{ "version": "2.2", "instance": { "limn-20260331xs1.htm": { "nsprefix": "limn", "nsuri": "http://www.liminatuspharma.com/20260331", "dts": { "schema": { "local": [ "limn-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "limn-20260331_cal.xml" ] }, "definitionLink": { "local": [ "limn-20260331_def.xml" ] }, "labelLink": { "local": [ "limn-20260331_lab.xml" ] }, "presentationLink": { "local": [ "limn-20260331_pre.xml" ] }, "inline": { "local": [ "limn-20260331xs1.htm" ] } }, "keyStandard": 158, "keyCustom": 118, "axisStandard": 19, "axisCustom": 0, "memberStandard": 19, "memberCustom": 76, "hidden": { "total": 27, "http://fasb.org/us-gaap/2025": 22, "http://www.liminatuspharma.com/20260331": 3, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 326, "entityCount": 1, "segmentCount": 95, "elementCount": 466, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 876, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation", "longName": "1100090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "1100100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R3": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "longName": "1100105 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesOutstanding", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R4": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "1100200 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "longName": "1100300 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Deficit", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0P2Hk6Fm0UCfvB5hIDbvbw", "name": "limn:StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R6": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical", "longName": "1100305 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "limn:OfferingCosts", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "1100400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations", "longName": "1110101 - Disclosure - Description of Organization and Business Operations", "shortName": "Description of Organization and Business Operations", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies", "longName": "1110201 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreements", "longName": "1110301 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "limn:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions", "longName": "1110401 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://www.liminatuspharma.com/role/DisclosureDebt", "longName": "1110501 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquity", "longName": "1110601 - Disclosure - Stockholder's Equity", "shortName": "Stockholder's Equity", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R14": { "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies", "longName": "1110701 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements", "longName": "1110801 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEvents", "longName": "1110901 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "1120202 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://www.liminatuspharma.com/role/DisclosureDebtTables", "longName": "1130503 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables", "longName": "1130603 - Disclosure - Stockholder's Equity (Tables)", "shortName": "Stockholder's Equity (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables", "longName": "1130803 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "longName": "1140101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)", "shortName": "Description of Organization and Business Operations - Business Combination (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "As_Of_4_30_2025_4J97pfd8ekmuXZKeWcY-QA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "longName": "1140102 - Disclosure - Description of Organization and Business Operations - February 2026 Public Offering (Details)", "shortName": "Description of Organization and Business Operations - February 2026 Public Offering (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "longName": "1140103 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)", "shortName": "Description of Organization and Business Operations - Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "1140201 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "shortName": "Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockPurchaseWarrantsMember_JogJT3JKnkStw7CCF--1Dw", "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "limn:NetIncomeLossPerCommonStockPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R25": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails", "longName": "1140202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)", "shortName": "Significant Accounting Policies - Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "longName": "1140301 - Disclosure - License Agreements - CD47 License (Details)", "shortName": "License Agreements - CD47 License (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_tzr9osJ2S0C-6yY56Bt5Ug", "name": "limn:EstimatedPercentageOfActivitiesCompleted", "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "limn:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R27": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "longName": "1140401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)", "shortName": "Related Party Transactions - Feelux Bonds (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "longName": "1140402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)", "shortName": "Related Party Transactions - Car-Tcellkor Loan (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "longName": "1140403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)", "shortName": "Related Party Transactions - Valetudo Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "longName": "1140404 - Disclosure - Related Party Transactions - Ewon Loans (Details)", "shortName": "Related Party Transactions - Ewon Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "longName": "1140405 - Disclosure - Related Party Transactions - Prophase Loans (Details)", "shortName": "Related Party Transactions - Prophase Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "longName": "1140406 - Disclosure - Related Party Transactions - Hana Loans (Details)", "shortName": "Related Party Transactions - Hana Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "longName": "1140407 - Disclosure - Related Party Transactions - Amantes Loans (Details)", "shortName": "Related Party Transactions - Amantes Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "longName": "1140408 - Disclosure - Related Party Transactions - Due to Related Party (Details)", "shortName": "Related Party Transactions - Due to Related Party (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "longName": "1140501 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "longName": "1140601 - Disclosure - Stockholder's Equity (Details)", "shortName": "Stockholder's Equity (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_2_19_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_PreFundedWarrantsMember_nVZL2iH4ikeTyIHCOmUqAA", "name": "limn:ClassOfWarrantOrRightNumberOfWarrantsExercised", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R37": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails", "longName": "1140602 - Disclosure - Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)", "shortName": "Stockholder's Equity - Assumptions used for estimating fair value of warrants (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_2_18_2026_us-gaap_ClassOfWarrantOrRightAxis_limn_CommonStockWarrantsAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_KxviRH7DfUuHBTu5r6l8NQ", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "longName": "1140603 - Disclosure - Stockholder's Equity - Offering proceeds and related issuance costs (Details)", "shortName": "Stockholder's Equity - Offering proceeds and related issuance costs (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "limn:GrossProceedsFromIssuanceOfWarrants", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "limn:GrossProceedsFromIssuanceOfWarrants", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "limn:ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "1140701 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ShortTermLeaseCost", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "longName": "1140801 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "longName": "1140802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)", "shortName": "Fair Value Measurements - Changes in fair value of Level 3 (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets", "longName": "1200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Uncategorized", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA", "name": "limn:AccruedMaintenanceFeeCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R43": { "role": "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals", "longName": "1200105 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Cover", "order": "43", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg", "name": "limn:CommonStockShareOutstanding", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R44": { "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations", "longName": "1200200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit", "longName": "1200300 - Statement - Consolidated Statements of Changes in Stockholder's Deficit", "shortName": "Consolidated Statements of Changes in Stockholder's Deficit", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "45", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HFF_MgUngEePnxJ9ysVB6Q", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QtWe4qLu3ECx2YHcibyoSg", "name": "limn:SharesIssuedForSurrenderAndCancellationOfWarrants", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R46": { "role": "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "1200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_3_31_2025_ejBZY_8uOkmdKV2lzEKtuw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss", "longName": "1210101 - Disclosure - Description of Organization and Business Operations", "shortName": "Description of Organization and Business Operations", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess", "longName": "1210201 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss", "longName": "1210301 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "limn:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss", "longName": "1210401 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.liminatuspharma.com/role/DisclosureDebts", "longName": "1210501 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys", "longName": "1210601 - Disclosure - Stockholder's Equity", "shortName": "Stockholder's Equity", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess", "longName": "1210701 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss", "longName": "1210801 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxes", "longName": "1210901 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEventss", "longName": "1211001 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess", "longName": "1220202 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "policies", "menuCat": "Policies", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.liminatuspharma.com/role/DisclosureDebtTabless", "longName": "1230503 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless", "longName": "1230803 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables", "longName": "1230903 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "longName": "1240101 - Disclosure - Description of Organization and Business Operations - Business Combination (Details)", "shortName": "Description of Organization and Business Operations - Business Combination (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "longName": "1240102 - Disclosure - Description of Organization and Business Operations - Liquidity and Capital Resources (Details)", "shortName": "Description of Organization and Business Operations - Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "longName": "1240201 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "shortName": "Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_HN4XshJCLkKXZhXldn-OIA", "name": "us-gaap:AllowanceForNotesAndLoansReceivableCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:AllowanceForNotesAndLoansReceivableCurrent", "p", "us-gaap:FinanceLoansAndLeasesReceivablePolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R64": { "role": "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss", "longName": "1240202 - Disclosure - Significant Accounting Policies - Income Taxes (Details)", "shortName": "Significant Accounting Policies - Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "longName": "1240301 - Disclosure - License Agreements - CAR-T Products License (Details)", "shortName": "License Agreements - CAR-T Products License (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A", "name": "limn:UpfrontPaymentOfLicenseAgreementFees", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "limn:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_LicenseAndDevelopmentAgreementWithTdtMember_PCxMs4QP-k2uBuXoZKiE1A", "name": "limn:UpfrontPaymentOfLicenseAgreementFees", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "limn:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "longName": "1240302 - Disclosure - License Agreements - Vaccine Products License (Details)", "shortName": "License Agreements - Vaccine Products License (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "limn:ForgivenessOfUnrelatedVendorPayable", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_10_2020_To_4_10_2020_srt_ProductOrServiceAxis_limn_VaccineProductsAndVaccineDiagnosticsMember_us-gaap_TypeOfArrangementAxis_limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember_o6DHM9UbBkSNjCOhIS_9VA", "name": "limn:UpfrontPaymentOfLicenseAgreementFees", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "limn:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R67": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "longName": "1240303 - Disclosure - License Agreements - Termination of license agreement (Details)", "shortName": "License Agreements - Termination of license agreement (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg", "name": "limn:LicenseAgreementsTerminationAmountDue", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_TypeOfArrangementAxis_limn_CarTLicenseAndVaccineLicenseWithTdtMember_mWk8tah9gUuCRPqsFLhQWg", "name": "limn:LicenseAgreementsTerminationAmountDue", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "longName": "1240304 - Disclosure - License Agreements - CD47 License (Details)", "shortName": "License Agreements - CD47 License (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_10_31_2022_srt_CounterpartyNameAxis_limn_CurisBiotechHoldingsLlcMember_us-gaap_CapitalUnitsByClassAxis_us-gaap_CapitalUnitClassAMember_us-gaap_TypeOfArrangementAxis_limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember_MfcULb3sYEWNTNOdJMM4Mg", "name": "limn:NumberOfUnitsExchangeForLicenseRights", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "limn:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R69": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "longName": "1240401 - Disclosure - Related Party Transactions - Feelux Bonds (Details)", "shortName": "Related Party Transactions - Feelux Bonds (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "longName": "1240402 - Disclosure - Related Party Transactions - Car-Tcellkor Loan (Details)", "shortName": "Related Party Transactions - Car-Tcellkor Loan (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "longName": "1240403 - Disclosure - Related Party Transactions - Valetudo Loans (Details)", "shortName": "Related Party Transactions - Valetudo Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "longName": "1240404 - Disclosure - Related Party Transactions - Ewon Loans (Details)", "shortName": "Related Party Transactions - Ewon Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R73": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "longName": "1240405 - Disclosure - Related Party Transactions - Prophase Loans (Details)", "shortName": "Related Party Transactions - Prophase Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "longName": "1240406 - Disclosure - Related Party Transactions - Hana Loans (Details)", "shortName": "Related Party Transactions - Hana Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "longName": "1240407 - Disclosure - Related Party Transactions - Amantes Loans (Details)", "shortName": "Related Party Transactions - Amantes Loans (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R76": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "longName": "1240408 - Disclosure - Related Party Transactions - Due to Related Party (Details)", "shortName": "Related Party Transactions - Due to Related Party (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_y6Lx3mXqwk-nBkJ5KlLBYg", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R77": { "role": "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "longName": "1240409 - Disclosure - Related Party Transactions - Viral Gene (Details)", "shortName": "Related Party Transactions - Viral Gene (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "limn:OtherReceivableWriteOff", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_CounterpartyNameAxis_limn_ViralGeneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_7wxNNnmVW0OOyrl6dcdkLg", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R78": { "role": "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "longName": "1240501 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:ShortTermBorrowings", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "longName": "1240601 - Disclosure - Stockholder's Equity (Details)", "shortName": "Stockholder's Equity (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_3_31_2026_L6SW3BkQl0WZMPDFvkz15A", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_flys3WJksEO8Fjw5YgLAHw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "longName": "1240701 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_wVeW5R8HhEqrHEJsUZ-Amw", "name": "us-gaap:ShortTermLeaseCost", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R81": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss", "longName": "1240801 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_doQ-5t8E_kahW9UFnsMLNA", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R82": { "role": "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss", "longName": "1240802 - Disclosure - Fair Value Measurements - Changes in fair value of Level 3 (Details)", "shortName": "Fair Value Measurements - Changes in fair value of Level 3 (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_NOD7vwuXLUmAhk-2mkyvLQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "limn:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails", "longName": "1240901 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "limn:ResearchAndDevelopmentExpenseMandatoryCapitalization", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "limn:ResearchAndDevelopmentExpenseMandatoryCapitalization", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } }, "R84": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails", "longName": "1240902 - Disclosure - Income Taxes - Income tax provision (Details)", "shortName": "Income Taxes - Income tax provision (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails", "longName": "1240903 - Disclosure - Income Taxes - Reconciliation of income tax rate (Details)", "shortName": "Income Taxes - Reconciliation of income tax rate (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_irQx2sIGBEm7OXaxKeybww", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure__BtN5C3F7EGi9sFOid0_MA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "longName": "1240904 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)", "shortName": "Income Taxes - Deferred tax assets and liabilities (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_Hf4W2kCm00i9XO5kd_86yQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails", "longName": "1241001 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_12_31_2025_OelXbxjhz0yiR_6fjTSBcg", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_N6pBret940W8RpAQMc6Yqw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_2_17_2026_To_2_17_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_limn_BestEffortsPublicOfferingMember_809IbYMTbUCQEIVjWuaGsA", "name": "limn:PeriodOfNonIssuanceOfCommonStockFollowingClosingDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xs1.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r19", "r20" ] }, "limn_AccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AccruedInterestCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest as of the balance sheet date.", "label": "Accrued Interest, Current", "terseLabel": "Accrued interest, related parties" } } }, "auth_ref": [] }, "limn_AccruedMaintenanceFeeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AccruedMaintenanceFeeCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued maintenance fee as of balance sheet date.", "label": "Accrued Maintenance Fee, Current", "terseLabel": "Accrued maintenance fee" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r29", "r731", "r966" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid in Capital", "verboseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r574", "r847", "r848", "r849", "r850", "r903", "r969" ] }, "limn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfLoans", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease to additional paid in capital (APIC) resulting from Settlement of loans.", "label": "Adjustments to Additional Paid in Capital, Settlement of Loans", "negatedLabel": "Settlement of loans to Iris Acquisition Corp upon closing of the business combination" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllowanceForNotesAndLoansReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit Loss, Current", "terseLabel": "Credit losses relating to loan receivable", "documentation": "Amount of allowance for credit loss on financing receivable, classified as current." } } }, "auth_ref": [ "r79", "r159", "r194" ] }, "limn_AltaPartnersLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AltaPartnersLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Alta Partners Llc..", "label": "Alta Partners Llc [Member]", "terseLabel": "Alta Partners Llc" } } }, "auth_ref": [] }, "limn_AmantesJanuary2025LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AmantesJanuary2025LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Amantes January 2025 Loans.", "label": "Amantes January 2025 Loans [Member]", "terseLabel": "Amantes January 2025 Loans", "verboseLabel": "Amantes January 2025 Loans" } } }, "auth_ref": [] }, "limn_AmantesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AmantesLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Amantes LLC .", "label": "Amantes LLC [Member]", "terseLabel": "Amantes" } } }, "auth_ref": [] }, "limn_AmantesLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AmantesLoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Amantes Loans.", "label": "Amantes Loans [Member]", "terseLabel": "Amantes Loans" } } }, "auth_ref": [] }, "limn_AmantesNovember2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AmantesNovember2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Amantes November 2024 Loans.", "label": "Amantes November 2024 Loans [Member]", "terseLabel": "Amantes November 2024 Loans" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "limn_AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "AnnualSalesOfPeriodFromFirstCommercialSaleUntilPatentExpiresMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining scenario being the net sale of period from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.", "label": "Annual Sales Of Period From First Commercial Sale Until Patent Expires [Member]", "terseLabel": "Net sales of period from first commercial sale until patent expires" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r409" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r49", "r56", "r75", "r95", "r97", "r98", "r134", "r142", "r153", "r154", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r411", "r415", "r455", "r520", "r521", "r527", "r611", "r687", "r688", "r698", "r731", "r737", "r738", "r750", "r883", "r884", "r924" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r72", "r80", "r95", "r97", "r98", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r411", "r415", "r455", "r731", "r883", "r884", "r924" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r95", "r97", "r98", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r411", "r415", "r455", "r883", "r884", "r924" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r835" ] }, "limn_BestEffortsPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "BestEffortsPublicOfferingMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Best Efforts Public Offering.", "label": "Best Efforts Public Offering [Member]", "terseLabel": "Best efforts" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Business Combination [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r559", "r707", "r708", "r896", "r897", "r898" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Business Combination [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r559", "r707", "r708", "r896", "r897", "r898" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" ], "lang": { "en-us": { "role": { "label": "Business Combination [Line Items]", "terseLabel": "Description of Organization and Business Operations", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r203", "r354", "r355", "r356", "r357", "r363", "r364", "r365", "r366", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r401", "r402", "r403", "r406", "r712", "r715", "r896", "r897", "r898" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Liability Assumed, Liability", "terseLabel": "Recognized liability assumed", "documentation": "Amount of liability assumed in business combination and recognized at acquisition date." } } }, "auth_ref": [ "r379", "r384" ] }, "us-gaap_CapitalUnitClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CapitalUnitClassAMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "label": "Capital Unit, Class A [Member]", "terseLabel": "Class A Member Units", "documentation": "Class A of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CapitalUnitClassDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "label": "Capital Unit, Class [Domain]", "documentation": "Description of the type or class of capital units or capital shares." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsByClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CapitalUnitsByClassAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "label": "Capital Units by Class [Axis]", "documentation": "Information by type or class of the entity's capital units." } } }, "auth_ref": [] }, "limn_CarTLicenseAndVaccineLicenseWithTdtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CarTLicenseAndVaccineLicenseWithTdtMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to CAR-T Products and Vaccine Licenses.", "label": "CAR T License And Vaccine License With Tdt [Member]", "terseLabel": "CAR-T License and Vaccine License with TDT" } } }, "auth_ref": [] }, "limn_CarTcellkorLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CarTcellkorLoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Car-Tcellkor Loan.", "label": "Car Tcellkor Loan [Member]", "terseLabel": "Car-Tcellkor Loan" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r58", "r530", "r586", "r606", "r731", "r737", "r738", "r750", "r777" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r12" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation", "periodEndLabel": "Cash, end of the period", "periodStartLabel": "Cash, beginning of the period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r11", "r40", "r92" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation", "totalLabel": "Net change in cash", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r40" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r777", "r935" ] }, "limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "Cd47LicenseAndDevelopmentAgreementWithInnobationMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Metavagen License Agreement with respects to license right to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.", "label": "CD47 License And Development Agreement With InnoBation [Member]", "terseLabel": "CD47 License agreement with InnoBation" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "auth_ref": [ "r858" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r62", "r76", "r77", "r78", "r95", "r98", "r124", "r128", "r130", "r132", "r136", "r137", "r191", "r223", "r225", "r226", "r227", "r230", "r231", "r263", "r264", "r266", "r267", "r269", "r272", "r275", "r276", "r279", "r282", "r289", "r455", "r564", "r565", "r566", "r567", "r574", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r587", "r598", "r619", "r641", "r654", "r655", "r656", "r657", "r658", "r765", "r838", "r840", "r851" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r887" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Price per share (in dollars per share)", "verboseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r95", "r100", "r290" ] }, "limn_ClassOfWarrantOrRightIssuePricePerWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightIssuePricePerWarrant", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Per unit amount of warrants issued.", "label": "Class of Warrant or Right, Issue Price Per Warrant", "terseLabel": "Offering price of pre-funded warrants (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Stockholders' Equity", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares called by each warrant (in shares)", "verboseLabel": "Number of shares called by each warrant", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants to purchase shares issued (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r290" ] }, "limn_ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesSurrenderedAndCanceled", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants surrendered and canceled.", "label": "Class Of Warrant Or Right, Number Of Securities Surrendered And Canceled", "terseLabel": "Surrender and cancellation of warrants to purchase shares of common stock" } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightNumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised.", "label": "Class of Warrant or Right, Number Of Warrants Exercised", "terseLabel": "Pre-Funded warrants exercised" } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightNumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Class of Warrant or Right, Number of Warrants Issued", "terseLabel": "Pre-funded warrants (in shares)" } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssuedOnConversions", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued on conversion.", "label": "Class of Warrant or Right, Number of Warrants Issued on Conversions", "verboseLabel": "Pre-funded warrants issued on conversion (in shares)" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants issued (in shares)", "verboseLabel": "Warrants issued", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Consecutive Trading Days", "terseLabel": "Threshold number of specified consecutive trading days for stock price" } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, Threshold Trading Days", "terseLabel": "Threshold number of specified trading days for stock price" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r887" ] }, "limn_ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption": { "xbrltype": "perShareItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightThresholdSharePriceTriggerForRedemption", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "The threshold trigger price for redemption of warrants.", "label": "Class Of Warrant Or Right, Threshold Share Price Trigger For Redemption", "terseLabel": "Threshold Share Price for redemption of warrants" } } }, "auth_ref": [] }, "limn_ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClassOfWarrantOrRightThresholdWrittenNoticePeriodForRedemptionOfWarrants", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "The threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right, Threshold Written Notice Period For Redemption Of Warrants", "terseLabel": "Threshold written notice period for redemption of warrants" } } }, "auth_ref": [] }, "limn_ClearStreetLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ClearStreetLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Clear Street LLC", "label": "Clear Street Llc [Member]", "terseLabel": "Clear Street Llc" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "License Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r409" ] }, "limn_CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommercializeChimericAntigenReceptorAndCarTDiagnosticsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to product being commercialize chimeric antigen receptor (\"CAR-T\") and CAR-T Diagnostics.", "label": "Commercialize Chimeric Antigen Receptor And CAR-T Diagnostics [Member]", "terseLabel": "CAR-T products and CAR-T Diagnostics" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r25", "r52", "r529", "r597" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingencies", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciess" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r44", "r215", "r216", "r664", "r872", "r877" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonClassAMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Class A shares", "verboseLabel": "Common Stock", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r969" ] }, "limn_CommonStockAndPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockAndPreFundedWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock and pre-funded warrants.", "label": "Common Stock and Pre Funded Warrants [Member]", "terseLabel": "Common stock and Pre-Funded Warrants" } } }, "auth_ref": [] }, "limn_CommonStockCashRedemptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockCashRedemptionAmount", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Aggregate cash redemption of value of common stock of the entity.", "label": "Common Stock, Cash Redemption Amount", "terseLabel": "Aggregate cash redemption amount" } } }, "auth_ref": [] }, "limn_CommonStockCashRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockCashRedemptionPricePerShare", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the common stock of the entity is redeemed or may be called at.", "label": "Common Stock, Cash Redemption Price Per Share", "terseLabel": "Cash redemption price per share (in dollars per share)", "verboseLabel": "Cash redemption price per share" } } }, "auth_ref": [] }, "limn_CommonStockCashRedemptionShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockCashRedemptionShares", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of common shares redeemed for cash.", "label": "Common Stock, Cash Redemption, Shares", "terseLabel": "Shares redeemed (in shares)", "verboseLabel": "Shares redeemed" } } }, "auth_ref": [] }, "limn_CommonStockConversionRatioBusinessCombination": { "xbrltype": "pureItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockConversionRatioBusinessCombination", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of common stock in business combination.", "label": "Common Stock, Conversion Ratio, Business Combination", "terseLabel": "Number of common shares converted" } } }, "auth_ref": [] }, "limn_CommonStockIssuedInConnectionWithSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockIssuedInConnectionWithSettlement", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in connection with settlement in noncash financing activities.", "label": "Common Stock Issued In Connection With Settlement", "terseLabel": "Issuance of common stock in connection with the Clear Street settlement" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r740", "r741", "r742", "r744", "r745", "r746", "r747", "r847", "r848", "r850", "r903", "r965", "r969" ] }, "limn_CommonStockNumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockNumberOfVotesPerShare", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of votes for each share of common stock.", "label": "Common Stock, Number Of Votes Per Share", "terseLabel": "Number of votes per share" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r28" ] }, "limn_CommonStockPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockPayable", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Fair value of common stock payable.", "label": "Common Stock Payable", "terseLabel": "Settlement payable" } } }, "auth_ref": [] }, "limn_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock purchase warrants", "label": "Common Stock Purchase Warrants [Member]", "terseLabel": "Common stock purchase warrants" } } }, "auth_ref": [] }, "limn_CommonStockShareOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockShareOutstanding", "presentation": [ "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Share Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "verboseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r28", "r598" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r28", "r598", "r617", "r969", "r970" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 44,877,633 and 27,064,633 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively", "verboseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r28", "r264", "r271", "r532", "r731" ] }, "limn_CommonStockWarrantsAndPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockWarrantsAndPlacementAgentWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock warrants and placement agent warrants.", "label": "Common Stock Warrants and Placement Agent Warrants [Member]", "terseLabel": "Common Stock Warrants and Placement Agent Warrants" } } }, "auth_ref": [] }, "limn_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CommonStockWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax asset" } } }, "auth_ref": [] }, "limn_ConsortiumLoanOfRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ConsortiumLoanOfRelatedPartiesMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to consortium loan of related parties.", "label": "Consortium Loan of Related Parties [Member]", "terseLabel": "Consortium Loan of related parties" } } }, "auth_ref": [] }, "limn_ConversionOfAccruedInterestOnRelatedPartyDebts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ConversionOfAccruedInterestOnRelatedPartyDebts", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest on related party debts that were converted into common stock.", "label": "Conversion of Accrued Interest on Related party Debts", "terseLabel": "Accrued interest" } } }, "auth_ref": [] }, "limn_ConversionOfPrincipalAndAccruedInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ConversionOfPrincipalAndAccruedInterestAmount", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of conversion of principal and accrued interest amount.", "label": "Conversion of Principal and Accrued Interest Amount", "terseLabel": "Conversion of principal and accrued interest amount" } } }, "auth_ref": [] }, "limn_ConversionOfPrincipalAndAccruedInterestShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ConversionOfPrincipalAndAccruedInterestShares", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Shares of conversion of principal and accrued interest.", "label": "Conversion of Principal and Accrued Interest Shares", "terseLabel": "Conversion of principal and accrued interest shares (in shares)", "verboseLabel": "Conversion of principal and accrued interest shares" } } }, "auth_ref": [] }, "limn_ConversionOfStockOrUnitConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ConversionOfStockOrUnitConversionRatio", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of common stock issuable upon conversion of each share of stock or unit to be converted.", "label": "Conversion Of Stock Or Unit, Conversion Ratio", "terseLabel": "Share conversion ratio" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of stock (in shares)", "verboseLabel": "Conversion of stock", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r14", "r15", "r16" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "terseLabel": "Number of shares converted into (in shares)", "verboseLabel": "Number of shares converted into", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r14", "r15", "r16" ] }, "us-gaap_CostMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostMaintenance", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost, Maintenance", "terseLabel": "Annual maintenance fees", "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered." } } }, "auth_ref": [ "r791" ] }, "limn_CostsIncurredInConnectionWithIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CostsIncurredInConnectionWithIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of common stock issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Costs Incurred In Connection With Issuance Of Common Stock", "terseLabel": "Costs incurred in connection with the issuance of common stock" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r95", "r103", "r104", "r236", "r277", "r478", "r499", "r526", "r670", "r671", "r672", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r899", "r900", "r901", "r902" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "limn_CurisBiotechHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "CurisBiotechHoldingsLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Metavagen LLC (\"Metavagen\") owned by Chris Kim, the CEO of Liminatus.", "label": "Curis Biotech Holdings Llc [Member]", "terseLabel": "Curis Biotech Holdings LLC" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Conversion of outstanding principal", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r14", "r16" ] }, "limn_DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DebtConversionNoncashImpactToAdditionalPaidInCapitalForForgivenessOfAccruedInterest", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash impact to additional paid in capital upon forgiveness of accrued interest on the converted debt instrument in a non-cash transaction.", "label": "Debt Conversion, Noncash Impact To Additional paid In Capital For Forgiveness Of Accrued Interest", "terseLabel": "Non-cash impact to APIC for the forgiveness of accrued interest on converted related party debt" } } }, "auth_ref": [] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Conversion of related party short-term debt into common stock", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r14", "r16" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebt", "http://www.liminatuspharma.com/role/DisclosureDebts" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r45", "r95", "r96", "r210", "r211", "r212", "r213", "r214", "r221", "r222", "r232", "r238", "r239", "r240", "r241", "r242", "r243", "r248", "r255", "r256", "r258", "r417", "r464" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r6", "r19", "r20", "r50", "r51", "r233", "r234", "r235", "r236", "r237", "r239", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r693", "r694", "r695", "r696", "r697", "r729", "r836", "r837", "r839", "r846", "r873", "r874", "r875", "r920", "r921", "r933" ] }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentDecreaseForgiveness", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Consumption of outstanding principal", "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument." } } }, "auth_ref": [ "r836", "r839" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r22", "r259", "r464", "r465", "r729" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt interest rate", "verboseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r22", "r234" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r6", "r233", "r234", "r235", "r236", "r237", "r239", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r693", "r694", "r695", "r696", "r697", "r729", "r836", "r837", "r839", "r846", "r873", "r874", "r875", "r920", "r921", "r933" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r886", "r919", "r920", "r921" ] }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r871" ] }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]", "terseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r871" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Transaction Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r74" ] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCostsCurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Current", "terseLabel": "Deferred transaction costs", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r779" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r836", "r842", "r894", "r895" ] }, "limn_DeferredOfferingCostsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredOfferingCostsNoncurrent", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of the carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.", "label": "Deferred Offering Costs Noncurrent", "verboseLabel": "Deferred underwriting discount" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r836", "r842", "r894", "r895" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset, Interest Carryforward", "terseLabel": "Section 163(j) - Interest", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r892" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "terseLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r333" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax asset, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r891" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r892" ] }, "limn_DeferredTaxAssetsStartupExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredTaxAssetsStartupExpenses", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from startup expenses", "label": "Deferred Tax Assets, Startup Expenses", "terseLabel": "Startup expenses" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailss": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r334" ] }, "limn_DeferredTransactionCostsInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredTransactionCostsInAccountsPayable", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred transaction costs in accounts payable.", "label": "Deferred Transaction Costs In Accounts Payable", "terseLabel": "Deferred transaction costs in accounts payable" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of deferred underwriting discount on gross proceeds of the IPO.", "label": "Deferred Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering", "terseLabel": "Deferred underwriting discount (in percentage)" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeePayableSettledInCashUponConsummationOfBusinessCombination", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fee payable settled in cash upon consummation of business combination.", "label": "Deferred Underwriting Fee Payable Settled In Cash Upon Consummation Of Business Combination", "terseLabel": "Deferred underwriting fee payable settled in cash" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeePayableSettledInSharesUponConsummationOfBusinessCombination", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fee payable settled in shares upon consummation of business combination.", "label": "Deferred Underwriting Fee Payable Settled In Shares Upon Consummation Of Business Combination", "terseLabel": "Deferred underwriting fee payable settled in shares" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeePayableSettledUponConsummationOfBusinessCombination", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fee payable settled upon consummation of business combination.", "label": "Deferred Underwriting Fee Payable Settled Upon Consummation Of Business Combination", "terseLabel": "Deferred underwriting fees settled" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeeRemainingAmountSettlementUponConsummationOfCombinedCompanyNextShareOffering", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Remaining amount of deferred underwriting fee settled upon consummation of combined company next share offering.", "label": "Deferred Underwriting Fee, Remaining Amount Settlement Upon Consummation Of Combined Company Next Share Offering", "terseLabel": "Remaining amount of deferred underwriting fee settled" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeeWaivedUponConsummationOfBusinessCombination", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fee waived upon consummation of business combination.", "label": "Deferred Underwriting Fee Waived Upon Consummation Of Business Combination", "terseLabel": "Deferred underwriting fee waived" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeesPayableInCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeesPayableInCashCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fees payable in cash and are classified as current as of the balance sheet date.", "label": "Deferred Underwriting Fees Payable In Cash, Current", "terseLabel": "Deferred underwriting fee payable" } } }, "auth_ref": [] }, "limn_DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "DeferredUnderwritingFeesPayableToBeSettledInSharesUponConsummationOfBusinessCombination", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting fees liabilities of acquiree to be settled by way of issuance of common stock of the entity upon consummation of business combination.", "label": "Deferred Underwriting Fees Payable, To Be Settled In Shares Upon Consummation Of Business Combination", "terseLabel": "Deferred underwriting fees payable", "verboseLabel": "Deferred underwriting fees liabilities" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r17", "r88", "r673", "r674", "r676", "r678" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r65", "r87", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r122", "r124", "r130", "r131", "r132", "r133", "r262", "r312", "r352", "r408", "r431", "r432", "r519", "r541", "r680" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r65", "r87", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r124", "r130", "r131", "r132", "r133", "r262", "r312", "r352", "r408", "r431", "r432", "r519", "r541", "r680" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Income tax provision expense/(benefit)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r321", "r711" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r95", "r99", "r321", "r343", "r711" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r324", "r711", "r836", "r843", "r888" ] }, "limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityAmount", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability", "label": "Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Amount", "negatedLabel": "Fair value of common stock to be issued for contingent liability" } } }, "auth_ref": [] }, "limn_EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfCommonStockForContingentLiabilityPercent", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of common stock to be issued for contingent liability", "label": "Effective Income Tax Rate Reconciliation, Fair Value Of Common Stock For Contingent Liability, Percent", "terseLabel": "Fair value of common stock to be issued for contingent liability" } } }, "auth_ref": [] }, "limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockAmount", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain (loss) on exchange of common stock for warrants", "label": "Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Amount", "negatedLabel": "Loss on exchange of common stock for warrants" } } }, "auth_ref": [] }, "limn_EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationGainLossOnExchangeOfCommonStockPercent", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to gain loss on exchange of common stock for warrants", "label": "Effective Income Tax Rate Reconciliation, Gain (Loss) On Exchange Of Common Stock, Percent", "terseLabel": "Loss on exchange of common stock for warrants" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other permanent differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r711", "r836", "r843", "r888", "r889" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal expense", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r323", "r711", "r836", "r843", "r888" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration]", "documentation": "Indicates name of state or local jurisdiction that makes up greater than 50 percent of effect of state and local income tax." } } }, "auth_ref": [ "r325", "r711" ] }, "limn_EmergingGrowthCompanyPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EmergingGrowthCompanyPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policies on emerging growth company status.", "label": "Emerging Growth Company Policy [Policy Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "auth_ref": [] }, "limn_EmploymentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EmploymentAgreementMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to employment agreement.", "label": "Employment Agreement [Member]", "terseLabel": "Employment Agreement" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r751" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r751" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r764" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r751" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r751" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.liminatuspharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r751" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r63", "r64", "r65", "r84", "r85", "r86", "r105", "r106", "r107", "r109", "r116", "r118", "r120", "r135", "r192", "r193", "r209", "r261", "r291", "r312", "r341", "r342", "r349", "r350", "r351", "r353", "r407", "r408", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r457", "r458", "r459", "r460", "r461", "r462", "r466", "r467", "r471", "r539", "r552", "r553", "r554", "r574", "r641" ] }, "limn_EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EquitySettlementDeferredUnderwritingFeesEffectOfChangeInFairValue", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from change in fair value of deferred underwriting fees that would be settled in common stock of the combined entity.", "label": "Equity Settlement, Deferred Underwriting Fees, Effect Of Change In Fair Value", "negatedLabel": "Change in fair value of deferred underwriting fee - paid in common stock", "negatedTerseLabel": "Change in fair value of deferred underwriting fee - paid in common stock", "terseLabel": "Change in fair value of deferred underwriting fee - paid in common stock", "verboseLabel": "Change in fair value of deferred underwriting fee - paid in common stock" } } }, "auth_ref": [] }, "limn_EstimatedPercentageOfActivitiesCompleted": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EstimatedPercentageOfActivitiesCompleted", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "The estimated percentage of activities completed by the company as per agreement.", "label": "Estimated Percentage Of Activities Completed", "verboseLabel": "Percentage of activities completed" } } }, "auth_ref": [] }, "limn_EwonComfortechCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EwonComfortechCoLtdMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ewon Comfortech Co, Ltd.", "label": "Ewon Comfortech Co Ltd [Member]", "terseLabel": "Ewon Comfortech Co Ltd" } } }, "auth_ref": [] }, "limn_EwonDecember2022LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EwonDecember2022LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ewon December 2022 Loan.", "label": "Ewon December 2022 Loan [Member]", "terseLabel": "Ewon December 2022 Loan" } } }, "auth_ref": [] }, "limn_EwonDecember2023LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EwonDecember2023LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ewon December 2023 Loan.", "label": "Ewon December 2023 Loan [Member]", "terseLabel": "Ewon December 2023 Loan" } } }, "auth_ref": [] }, "limn_EwonLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EwonLoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ewon Loan.", "label": "Ewon Loan [Member]", "terseLabel": "Ewon Loan" } } }, "auth_ref": [] }, "limn_EwonSeptember2023LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "EwonSeptember2023LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ewon September 2023 Loan.", "label": "Ewon September 2023 Loan [Member]", "terseLabel": "Ewon September 2023 Loan" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in the fair value of warrant liabilities", "negatedTerseLabel": "Change in the fair value of warrant liability", "terseLabel": "Change in the fair value of warrant liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r3" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r434", "r435", "r445", "r719" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r434", "r435", "r445", "r719" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Stockholder's Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r436", "r437", "r438", "r712", "r714", "r721" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r436", "r437", "r438", "r712", "r714", "r721" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of assumptions used for estimating fair value of warrants", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r436", "r437", "r721" ] }, "limn_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets and liability using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset and liability.", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in fair value of Level 3 financial assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r246", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r433", "r435", "r436", "r437", "r438", "r444", "r445", "r447", "r453", "r486", "r487", "r488", "r668", "r694", "r695", "r702", "r703", "r704", "r705", "r706", "r719", "r721", "r728" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r434", "r435", "r436", "r438", "r719", "r908", "r913" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurements", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementss" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r436", "r441", "r442", "r443", "r444", "r447", "r448", "r449", "r450", "r451", "r517", "r719", "r722" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair value inputs level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r246", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r435", "r436", "r437", "r438", "r445", "r453", "r488", "r668", "r694", "r695", "r702", "r703", "r704", "r705", "r706", "r719", "r721", "r728" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r434", "r435", "r436", "r438", "r719", "r908", "r913" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Initial measurement at the Closing Date", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r440", "r446" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Change in fair value", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r910", "r912" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance, fair value", "periodStartLabel": "Beginning balance, fair value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r439", "r446" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r246", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r433", "r435", "r436", "r437", "r438", "r444", "r445", "r447", "r453", "r486", "r487", "r488", "r668", "r694", "r695", "r702", "r703", "r704", "r705", "r706", "r719", "r721", "r728" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value Measurements", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r719", "r905", "r906", "r907", "r908", "r909", "r913" ] }, "limn_FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FairValueOfCommonSharesIssuedForSettlementOfDeferredUnderwritingFees", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Fair value of common shares issued for settlement of deferred underwriting fees.", "label": "Fair Value Of Common Shares Issued For Settlement Of Deferred Underwriting Fees", "terseLabel": "Fair value of common shares" } } }, "auth_ref": [] }, "limn_FairValueOfCommonStockIssuanceForContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FairValueOfCommonStockIssuanceForContingentLiability", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 7.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense related to fair value of common stock to be issued for contingent liability.", "label": "Fair Value Of Common Stock Issuance For Contingent Liability", "negatedLabel": "Fair value of common stock to be issued for contingent liability", "terseLabel": "Fair value of common stock to be issued for contingent liability" } } }, "auth_ref": [] }, "limn_FairValueOfCommonStockIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FairValueOfCommonStockIssued", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "The fair value of common stock issued.", "label": "Fair Value of Common Stock Issued", "terseLabel": "Fair value of common stock" } } }, "auth_ref": [] }, "limn_FairValueOfWarrantsSurrendered": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FairValueOfWarrantsSurrendered", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "The fair value of warrants surrendered.", "label": "Fair Value of Warrants Surrendered", "terseLabel": "Fair value of warrants surrendered" } } }, "auth_ref": [] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Federal" } } }, "auth_ref": [] }, "limn_FederalIncomeTaxExpenseSubjectToLimitationInUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FederalIncomeTaxExpenseSubjectToLimitationInUse", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal Income Tax Expense Subject To Limitation In Use", "terseLabel": "Federal income tax liabilities, subject limitations" } } }, "auth_ref": [] }, "limn_FeeReductionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FeeReductionAgreementMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Fee reduction agreement.", "label": "Fee Reduction Agreement [Member]", "terseLabel": "Fee Reduction Agreement" } } }, "auth_ref": [] }, "limn_FeeluxAndCarTcellkorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FeeluxAndCarTcellkorMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Feelux and Car-Tcellkor.", "label": "Feelux and Car-Tcellkor [Member]", "terseLabel": "Feelux and Car-Tcellkor" } } }, "auth_ref": [] }, "limn_FeeluxBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FeeluxBondsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Feelux Bonds.", "label": "Feelux Bonds [Member]", "terseLabel": "Feelux Bonds" } } }, "auth_ref": [] }, "limn_FeeluxCo.LtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FeeluxCo.LtdMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Feelux bonds.", "label": "Feelux Co. Ltd [Member]", "terseLabel": "Feelux Co. Ltd" } } }, "auth_ref": [] }, "us-gaap_FinanceLoansAndLeasesReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinanceLoansAndLeasesReceivablePolicy", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Financing Receivable [Policy Text Block]", "terseLabel": "Loan Receivable", "documentation": "Disclosure of accounting policy for financing receivable." } } }, "auth_ref": [ "r160", "r860", "r861", "r862", "r863", "r864", "r865" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r257", "r287", "r417", "r428", "r452", "r454", "r456", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r525", "r540", "r692", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r732", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r866", "r867", "r868", "r869", "r904", "r907", "r908", "r909", "r911", "r913", "r914", "r915" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetails", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsDetailss" ], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Warrant liability", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r905", "r906", "r911", "r914", "r915", "r916", "r917" ] }, "limn_ForgivenessOfUnrelatedVendorPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ForgivenessOfUnrelatedVendorPayable", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of forgiveness of unrelated vendor payable.", "label": "Forgiveness Of Unrelated Vendor Payable", "negatedLabel": "Forgiveness of unrelated vendor payables", "terseLabel": "Forgiveness of unrelated vendor payables" } } }, "auth_ref": [] }, "limn_FranchiseTaxExpenseIncludingInterestAndPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "FranchiseTaxExpenseIncludingInterestAndPenalty", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of franchise tax expense and related interest and penalties incurred by the company during the period.", "label": "Franchise Tax Expense Including Interest And Penalty", "terseLabel": "Franchise tax, penalties and interest" } } }, "auth_ref": [] }, "limn_GainLossOnIssuanceOfCommonStockForWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "GainLossOnIssuanceOfCommonStockForWarrants", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "The profit or loss on exchange of common stock for surrender of warrants classified as non-operating income. Represents the difference in the fair value of common stock and warrants.", "label": "Gain (Loss) on Issuance of Common Stock for Warrants", "negatedLabel": "Loss on issuance of common stock in connection with the surrendar of warrants", "terseLabel": "Loss on issuance of common stock", "verboseLabel": "Loss on exchange of common stock for warrants" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r35", "r621" ] }, "limn_GrossProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "GrossProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Gross Proceeds from Issuance of Warrants", "terseLabel": "Allocated Gross Proceeds" } } }, "auth_ref": [] }, "limn_HanaAugust2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "HanaAugust2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hana August 2024 Loans.", "label": "Hana August 2024 Loans [Member]", "terseLabel": "Hana August 2024 Loans" } } }, "auth_ref": [] }, "limn_HanaImmunotherapeuticsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "HanaImmunotherapeuticsLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hana Immunotherapeutics, LLC.", "label": "Hana Immunotherapeutics, LLC [Member]", "terseLabel": "Hana Immunotherapeutics, LLC" } } }, "auth_ref": [] }, "limn_HanaLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "HanaLoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hana Loans.", "label": "Hana Loans [Member]", "terseLabel": "Hana Loans" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r95", "r99", "r316", "r321", "r325", "r326", "r327", "r330", "r336", "r344", "r346", "r347", "r348", "r524", "r558", "r569", "r711" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r890" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails", "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision expense/(benefit)", "totalLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r57", "r61", "r95", "r119", "r120", "r134", "r145", "r154", "r320", "r321", "r345", "r542", "r675", "r677", "r679", "r711" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r83", "r318", "r319", "r330", "r331", "r335", "r340", "r563" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r324", "r711", "r888" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Statutory federal income tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r321", "r711" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other permanent differences", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r711", "r888", "r889" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes, net of federal expense", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r323", "r711", "r888" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "verboseLabel": "Income tax obligations", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r13", "r91", "r337", "r338" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "limn_IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "IncreaseDecreaseInAccruedInterestToRelatedPartyCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued interest to related party classified as current.", "label": "Increase (Decrease) In Accrued Interest to Related Party, Current", "negatedLabel": "Accrued interest, related parties" } } }, "auth_ref": [] }, "limn_IncreaseDecreaseInAccruedMaintenanceFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "IncreaseDecreaseInAccruedMaintenanceFeesCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued maintenance fee classified as current.", "label": "Increase (Decrease) In Accrued Maintenance Fees, Current", "negatedLabel": "Accrued maintenance fee" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due from Related Parties, Current", "negatedLabel": "Due from related party, current", "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Due to related parties", "verboseLabel": "Due to related party", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r2" ] }, "limn_IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "IncreaseDecreaseInDueToResearchAndDevelopmentPartnerCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in due to research and development partner classified as current.", "label": "Increase (Decrease) In Due to Research And Development Partner, Current", "negatedLabel": "Due to research and development partner" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Incremental common shares (in shares)", "verboseLabel": "Incremental common shares", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": [ "r125", "r126", "r127", "r132" ] }, "limn_InnobationBioCo.LtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "InnobationBioCo.LtdMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to InnoBation Bio Co. Ltd.", "label": "Innobation Bio Co. Ltd [Member]", "terseLabel": "Innobation Bio Co. Ltd" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense relating to loan", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r37", "r252", "r260", "r696", "r697", "r968" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense, related parties", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r144", "r675", "r679", "r793" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r134", "r143", "r154", "r687", "r792" ] }, "limn_IrisAcquisitionCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "IrisAcquisitionCorpMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Iris Acquisition Corp.", "label": "Iris Acquisition Corp [Member]", "terseLabel": "Iris" } } }, "auth_ref": [] }, "limn_IrisAcquisitionHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "IrisAcquisitionHoldingsLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Iris Acquisition Holdings, LLC.", "label": "Iris Acquisition Holdings, LLC [Member]", "terseLabel": "Iris Acquisition Holdings, LLC" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r468" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r922" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r6", "r19", "r20", "r21", "r23", "r24", "r25", "r26", "r95", "r97", "r98", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r412", "r415", "r416", "r455", "r596", "r682", "r698", "r750", "r883", "r924", "r925" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r33", "r53", "r534", "r731", "r737", "r738", "r836", "r841", "r870", "r918" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Liabilities Assumed", "terseLabel": "Liabilities assumed in connection with the Business Combination", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r14", "r15", "r16" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r21", "r73", "r95", "r97", "r98", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r412", "r415", "r416", "r455", "r731", "r883", "r924", "r925" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "limn_LiabilityOfUnderwritingFeesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LiabilityOfUnderwritingFeesFairValue", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of liability of underwriting fees fair value.", "label": "Liability of Underwriting Fees Fair Value", "terseLabel": "Liability of underwriting fees" } } }, "auth_ref": [] }, "limn_LicenseAgreementMaintenanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseAgreementMaintenanceFees", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of license agreement incurred in maintenance fees.", "label": "License agreement maintenance fees", "terseLabel": "Maintenance fee" } } }, "auth_ref": [] }, "limn_LicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "License Agreements" } } }, "auth_ref": [] }, "limn_LicenseAgreementsTerminationAmountDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseAgreementsTerminationAmountDue", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount owes pursuant to termination of license agreements by TDT.", "label": "License Agreements Termination, Amount Due", "terseLabel": "Amount owes pursuant to termination of license agreement" } } }, "auth_ref": [] }, "limn_LicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseAgreementsTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreements", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementss" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for License Agreements.", "label": "License Agreements [Text Block]", "terseLabel": "License Agreements" } } }, "auth_ref": [] }, "limn_LicenseAndDevelopmentAgreementWithTdtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseAndDevelopmentAgreementWithTdtMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to license and development agreement with TDT (the \"CAR-T License\"), whereby the Company received an exclusive license to develop and commercialize chimeric antigen receptor (\"CAR-T\") products and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a CAR-T product (the \"CAR-T Diagnostics\").", "label": "License And Development Agreement With Tdt [Member]", "terseLabel": "License And Development Agreement With TDT" } } }, "auth_ref": [] }, "limn_LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseMaximumAggregateMilestoneCommitmentsFundForFirstProductDevelopment", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum aggregate milestone commitment fund for first product development.", "label": "License Maximum Aggregate Milestone Commitments Fund For First Product Development", "terseLabel": "Maximum aggregate milestone commitment fund for first product development" } } }, "auth_ref": [] }, "limn_LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseMaximumMilestoneCommitmentFundForEachAdditionalProductDevelopment", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum milestone commitment fund for each additional product development.", "label": "License Maximum Milestone Commitment Fund For Each Additional Product Development", "terseLabel": "Maximum milestone commitment fund for each additional product development" } } }, "auth_ref": [] }, "limn_LicenseMilestoneCommitmentFundPayableForEachPhase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseMilestoneCommitmentFundPayableForEachPhase", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of license milestone commitment fund obligated to pay for each phase.", "label": "License Milestone Commitment Fund Payable For Each Phase", "terseLabel": "Amount of fund obligated to advance for each phase" } } }, "auth_ref": [] }, "limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "documentation": "Value of membership interest exchange for license fees being offset to additional paid-in capital.", "label": "License Rights, Value Of Units Offset From Additional Paid In Capital", "terseLabel": "Value of membership interest offset to additional paid-in capital" } } }, "auth_ref": [] }, "limn_LiminatusAndIrisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LiminatusAndIrisMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to business combination with Liminatus and Iris.", "label": "Liminatus And Iris [Member]", "terseLabel": "Liminatus and Iris" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LitigationSettlementInterest", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Interest", "terseLabel": "Litigation settlement interest", "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation." } } }, "auth_ref": [ "r769" ] }, "limn_LoansSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "LoansSettled", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of loans settled upon closing of merger in a non-cash transaction.", "label": "Loans Settled", "terseLabel": "Settlement of loans to Iris Acquisition Corp upon closing of the Business Combination" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss contingency on damaged value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": [ "r878", "r879", "r880" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r141", "r217", "r218", "r219", "r220", "r303", "r307", "r308", "r309", "r313", "r438", "r515", "r550", "r551", "r557", "r588", "r589", "r649", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r665", "r666", "r691", "r699", "r709", "r712", "r714", "r715", "r721", "r722", "r726", "r727", "r734", "r885", "r926", "r927", "r928", "r929", "r930", "r931" ] }, "limn_MaximumNumbersOfSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "MaximumNumbersOfSharesIssuable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares issuable to underwriters.", "label": "Maximum Numbers Of Shares Issuable", "terseLabel": "Number of shares issuable to underwriters" } } }, "auth_ref": [] }, "limn_MaximumReimbursementForPlacementAgentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "MaximumReimbursementForPlacementAgentExpenses", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum out-of-pocket costs and expenses incurred in connection with the Offering that will be reimbursed", "label": "Maximum Reimbursement For Placement Agent Expenses", "terseLabel": "Placement agent fee, maximum reimbursement" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividends", "verboseLabel": "Dividend yield", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r308", "r907", "r908", "r909" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected life of warrants (years)", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r306", "r907", "r908", "r909" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Option Volatility [Member]", "terseLabel": "Expected stock volatility", "verboseLabel": "Expected volatility", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r907", "r908", "r909" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r309", "r907", "r908", "r909" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r436", "r437", "r438", "r712", "r714", "r715", "r721" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r436", "r437", "r438", "r712", "r714", "r715", "r721" ] }, "limn_MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "MergerTransactionCostsIncurredInNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of transaction costs incurred upon closing of merger during the period in a non-cash or part non-cash transaction.", "label": "Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction", "terseLabel": "Transaction costs incurred upon closing of the Business Combination" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r141", "r217", "r218", "r219", "r220", "r303", "r307", "r308", "r309", "r313", "r438", "r515", "r550", "r551", "r557", "r588", "r589", "r649", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r665", "r666", "r691", "r699", "r709", "r712", "r714", "r715", "r721", "r722", "r726", "r734", "r885", "r926", "r927", "r928", "r929", "r930", "r931" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r90" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r90" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash Flows from Investing Activities:", "verboseLabel": "Cash Flows from Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r34", "r42", "r54", "r65", "r71", "r81", "r82", "r86", "r95", "r97", "r98", "r102", "r108", "r112", "r113", "r114", "r115", "r116", "r119", "r120", "r129", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r262", "r265", "r268", "r273", "r312", "r352", "r408", "r432", "r455", "r538", "r618", "r639", "r640", "r675", "r677", "r679", "r748", "r883" ] }, "limn_NetIncomeLossPerCommonStockPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NetIncomeLossPerCommonStockPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of policy for net income (loss) per common stock.", "label": "Net income (loss) per Common Stock Policy [Policy Text Block]", "terseLabel": "Net Loss per Share of Common Stock", "verboseLabel": "Net loss per Common Stock" } } }, "auth_ref": [] }, "limn_NetProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NetProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "The net cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Net Proceeds from Issuance of Warrants", "terseLabel": "Allocated Net Proceeds" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements - Not Yet Adopted", "verboseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "limn_NonRedeemableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NonRedeemableWarrantMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to non-redeemable warrant.", "label": "Non Redeemable Warrant [Member]", "terseLabel": "Non-redeemable warrant" } } }, "auth_ref": [] }, "limn_NoncashConversionOfAmountBorrowedForPipeFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NoncashConversionOfAmountBorrowedForPipeFunds", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of borrowed funds for PIPE transactions that are converted in a non-cash or part non-cash transactions. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Conversion Of Amount Borrowed For PIPE Funds", "terseLabel": "Non-cash conversion of short term debt, related parties for PIPE Funds" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "terseLabel": "Non related party", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r836", "r844", "r845" ] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Loan receivable", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r518", "r859" ] }, "limn_NumberOfMilestonePaymentsForEachAdditionalProductDevelopment": { "xbrltype": "integerItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NumberOfMilestonePaymentsForEachAdditionalProductDevelopment", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of milestone developmental and regulatory milestone payments for each additional product development.", "label": "Number Of Milestone Payments For Each Additional Product Development", "terseLabel": "Number of developmental and regulatory milestone payments for each additional product development" } } }, "auth_ref": [] }, "limn_NumberOfMilestonePaymentsForFirstProductDevelopment": { "xbrltype": "integerItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NumberOfMilestonePaymentsForFirstProductDevelopment", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of milestone developmental and regulatory milestone payments for first product development.", "label": "Number Of Milestone Payments For First Product Development", "terseLabel": "Number of developmental and regulatory milestone payments for first product development" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r688", "r853" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r684", "r690", "r853" ] }, "limn_NumberOfSharesHeldInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NumberOfSharesHeldInEachUnit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of common shares held in each Iris unit.", "label": "Number Of Shares Held In Each Unit", "terseLabel": "Number of shares held in each unit (in shares)", "verboseLabel": "Number of shares held in each unit" } } }, "auth_ref": [] }, "limn_NumberOfUnitsExchangeForLicenseRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NumberOfUnitsExchangeForLicenseRights", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.", "label": "Number Of Units Exchange For License Rights", "terseLabel": "Number of member units exchange for license rights to develop", "verboseLabel": "Number of member units exchange for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarker" } } }, "auth_ref": [] }, "limn_NumberOfWarrantsHeldInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "NumberOfWarrantsHeldInEachUnit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants held in each Iris unit.", "label": "Number Of Warrants Held In Each Unit", "terseLabel": "Number of warrants held in each unit (in shares)", "verboseLabel": "Number of warrants held in each unit" } } }, "auth_ref": [] }, "limn_OfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "OfferingCosts", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Amount of offering costs involved in the issuance of common stock.", "label": "Offering Costs", "terseLabel": "Offering costs", "verboseLabel": "Allocated Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r679" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "negatedLabel": "Loss from operations", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r55", "r675", "r679", "r683", "r852", "r854", "r855", "r856", "r857" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating losses", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r339" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationss" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Organization and Business Operations", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r48", "r66", "r67", "r69", "r560", "r561" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Due to related parties", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r731" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Due from related party, non-current", "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent." } } }, "auth_ref": [ "r778" ] }, "limn_OtherReceivableWriteOff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "OtherReceivableWriteOff", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of receivable deemed as uncollectible and written off.", "label": "Other Receivable, Write Off", "terseLabel": "Forgiveness of related party receivables", "verboseLabel": "Uncollectible due from related party" } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivables, Net, Current", "terseLabel": "Due from related party, current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "limn_PaymentForCostsAssociatedWithClinicalTrials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PaymentForCostsAssociatedWithClinicalTrials", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of payment made for costs associated with clinical trials.", "label": "Payment For Costs Associated With Clinical Trials", "terseLabel": "Company issued a payment" } } }, "auth_ref": [] }, "limn_PaymentOfOfferingCostsInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PaymentOfOfferingCostsInCash", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "The amount paid in cash for offering costs.", "label": "Payment of Offering Costs in Cash", "terseLabel": "Underwriting discount paid in cash" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Merger Related Costs, Financing Activities", "negatedLabel": "Payment of transaction costs", "documentation": "The cash outflow for financing costs associated with business combinations." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire businesses", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r8", "r392", "r712", "r713", "r716" ] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Loans Receivable", "negatedLabel": "Loans to Iris Acquisition Corp", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r38" ] }, "limn_PercentOfOfferingPriceRepresentingExercisePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PercentOfOfferingPriceRepresentingExercisePrice", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the public offering price for the shares of common stock and common warrants offered in the Offering representing exercise price.", "label": "Percent of Offering Price Representing Exercise Price", "terseLabel": "Percent of offering price" } } }, "auth_ref": [] }, "limn_PercentOfSharesIssuedInOffering": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PercentOfSharesIssuedInOffering", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock sold in the offering, threshold percentage on the total number of outstanding shares.", "label": "Percent Of Shares Issued In The Offering", "terseLabel": "Percent of shares issued" } } }, "auth_ref": [] }, "limn_PeriodOfNonIssuanceOfCommonStockFollowingClosingDate": { "xbrltype": "durationItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PeriodOfNonIssuanceOfCommonStockFollowingClosingDate", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period during which shares will not be issued after the closing date of the offering", "label": "Period Of Non Issuance Of Common Stock Following Closing Date", "terseLabel": "Period of non issuance of common stock following closing date" } } }, "auth_ref": [] }, "limn_PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate": { "xbrltype": "durationItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PeriodOfNonIssuanceOfCommonStockInvolvingVariableRateTransactionFollowingClosingDate", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period during which common stock or any securities convertible into or exercisable or exchangeable for shares of common stock involving a variable rate transaction will not be issued after the closing date of the offering.", "label": "Period Of Non Issuance Of Common Stock Involving Variable Rate Transaction Following Closing Date", "terseLabel": "Period of non issuance of common stock involving variable rate transaction following closing date" } } }, "auth_ref": [] }, "limn_PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PhaseIiAndPhaseIiiClinicalTrialsOfCarTProductMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Phase II and Phase III clinical trials of CAR-T product.", "label": "Phase II and Phase III Clinical Trials Of Car T Product [Member]", "terseLabel": "Phase II and Phase III clinical trials of CAR-T Product" } } }, "auth_ref": [] }, "limn_PlacementAgentCashFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PlacementAgentCashFeePercentage", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of cash fee for placement agent, calculated on aggregate gross proceeds raised.", "label": "Placement Agent Cash Fee, Percentage", "terseLabel": "Placement agent fee, percent" } } }, "auth_ref": [] }, "limn_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "auth_ref": [] }, "limn_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre funded warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-funded warrants", "verboseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r27", "r275" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r27", "r598" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r27", "r275" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r27", "r598", "r617", "r969", "r970" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r27", "r264", "r270", "r531", "r731" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r780" ] }, "limn_PrepaidResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PrepaidResearchAndDevelopmentExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of prepaid research and development classified as current.", "label": "Prepaid Research And Development Expense, Current", "terseLabel": "Prepaid research and development costs" } } }, "auth_ref": [] }, "limn_PrincipalAndAccruedInterestOnPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PrincipalAndAccruedInterestOnPrivatePlacement", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of principal and accrued interest converted into shares.", "label": "Principal and Accrued Interest on Private Placement", "terseLabel": "Principal and accrued interest" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrivatePlacementMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "limn_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private placement warrants.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private placement warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Total consideration", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds from issuance of common stock for PIPE investment", "verboseLabel": "Proceeds from issuance of common stock, net", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r1" ] }, "limn_ProceedsFromIssuanceOfPrivatePlacementInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProceedsFromIssuanceOfPrivatePlacementInvestor", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private placement investor rather than public placement.", "label": "Proceeds from Issuance of Private Placement Investor", "terseLabel": "Proceeds from issuance of private placement investor" } } }, "auth_ref": [] }, "limn_ProceedsFromIssuanceOfPrivatePlacementInvestorFunded": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProceedsFromIssuanceOfPrivatePlacementInvestorFunded", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from private placement investor funded indirectly.", "label": "Proceeds from Issuance of Private Placement Investor Funded", "terseLabel": "Proceeds from issuance of private placement investor funded" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Short-Term Debt", "terseLabel": "Proceeds from issuance of short-term debt, related party", "verboseLabel": "Proceeds from bonds", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r9" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r156", "r516", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r669", "r674", "r677", "r679", "r700", "r701", "r733", "r734", "r735", "r736", "r739", "r768", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r881", "r882", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r156", "r516", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r669", "r674", "r677", "r679", "r700", "r701", "r733", "r734", "r735", "r736", "r739", "r768", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r881", "r882", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r65", "r71", "r81", "r82", "r89", "r95", "r97", "r98", "r102", "r108", "r116", "r119", "r120", "r191", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r262", "r312", "r352", "r408", "r410", "r413", "r414", "r432", "r455", "r520", "r522", "r537", "r573", "r618", "r639", "r640", "r717", "r718", "r749", "r790", "r883" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r470", "r523", "r536", "r731" ] }, "limn_ProphaseApril2024LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseApril2024LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase April 2024 Loan.", "label": "Prophase April 2024 Loan [Member]", "terseLabel": "Prophase April 2024 Loan" } } }, "auth_ref": [] }, "limn_ProphaseApril2025LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseApril2025LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase April 2025 Loans.", "label": "Prophase April 2025 Loans [Member]", "terseLabel": "Prophase April 2025 Loans" } } }, "auth_ref": [] }, "limn_ProphaseAugust2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseAugust2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase August 2024 Loans.", "label": "Prophase August 2024 Loans [Member]", "terseLabel": "Prophase August 2024 Loans" } } }, "auth_ref": [] }, "limn_ProphaseFebruary2024LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseFebruary2024LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase February 2024 Loan.", "label": "Prophase February 2024 Loan [Member]", "terseLabel": "Prophase February 2024 Loan" } } }, "auth_ref": [] }, "limn_ProphaseFebruary2025LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseFebruary2025LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase February 2025 Loan.", "label": "Prophase February 2025 Loan [Member]", "terseLabel": "Prophase February 2025 Loan", "verboseLabel": "Prophase February 2025 Loan" } } }, "auth_ref": [] }, "limn_ProphaseFebruary2025LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseFebruary2025LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase February 2025 Loans.", "label": "Prophase February 2025 Loans [Member]", "terseLabel": "Prophase February 2025 Loan" } } }, "auth_ref": [] }, "limn_ProphaseJuly2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseJuly2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase July 2024 Loans.", "label": "Prophase July 2024 Loans [Member]", "terseLabel": "Prophase July 2024 Loans" } } }, "auth_ref": [] }, "limn_ProphaseLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseLoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase Loan.", "label": "Prophase Loan [Member]", "terseLabel": "Prophase Loan" } } }, "auth_ref": [] }, "limn_ProphaseMarch2024LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseMarch2024LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase March 2024 Loan.", "label": "Prophase March 2024 Loan [Member]", "terseLabel": "Prophase March 2024 Loan" } } }, "auth_ref": [] }, "limn_ProphaseMarch2025LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseMarch2025LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase March 2025 Loan.", "label": "Prophase March 2025 Loan [Member]", "terseLabel": "Prophase March 2025 Loan", "verboseLabel": "Prophase March 2025 Loan" } } }, "auth_ref": [] }, "limn_ProphaseMarch2025LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseMarch2025LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase March 2025 Loans.", "label": "Prophase March 2025 Loans [Member]", "terseLabel": "Prophase March 2025 Loans" } } }, "auth_ref": [] }, "limn_ProphaseMay2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseMay2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase May 2024 Loans.", "label": "Prophase May 2024 Loans [Member]", "terseLabel": "Prophase May 2024 Loans" } } }, "auth_ref": [] }, "limn_ProphaseSciencesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ProphaseSciencesLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prophase Sciences LLC .", "label": "Prophase Sciences LLC [Member]", "terseLabel": "Prophase" } } }, "auth_ref": [] }, "limn_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "PublicWarrantsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to public warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r141", "r217", "r218", "r219", "r220", "r292", "r303", "r307", "r308", "r309", "r311", "r313", "r438", "r489", "r498", "r515", "r550", "r551", "r557", "r588", "r589", "r649", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r665", "r666", "r691", "r699", "r709", "r712", "r714", "r715", "r721", "r722", "r726", "r727", "r734", "r742", "r876", "r885", "r908", "r927", "r928", "r929", "r930", "r931" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r141", "r217", "r218", "r219", "r220", "r292", "r303", "r307", "r308", "r309", "r311", "r313", "r438", "r489", "r498", "r515", "r550", "r551", "r557", "r588", "r589", "r649", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r665", "r666", "r691", "r699", "r709", "r712", "r714", "r715", "r721", "r722", "r726", "r727", "r734", "r742", "r876", "r885", "r908", "r927", "r928", "r929", "r930", "r931" ] }, "limn_RedeemableWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "RedeemableWarrantMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to redeemable warrant.", "label": "Redeemable Warrant [Member]", "terseLabel": "Redeemable warrant" } } }, "auth_ref": [] }, "limn_RelatedPartiesDebtToUnsecuredPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "RelatedPartiesDebtToUnsecuredPromissoryNote", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of borrowed from the related parties were used to fund an unsecured promissory note.", "label": "Related Parties Debt to Unsecured Promissory Note", "terseLabel": "Related parties debt" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r95", "r101", "r102", "r158", "r299", "r302", "r475", "r476", "r528", "r535", "r591", "r592", "r593", "r594", "r595", "r616", "r648", "r967" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r95", "r101", "r102", "r475", "r476", "r477", "r478", "r528", "r535", "r591", "r592", "r593", "r594", "r595", "r616", "r648" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Significant Accounting Policies", "verboseLabel": "Related Party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r95", "r101", "r102", "r158", "r475", "r476", "r478", "r622", "r623", "r626" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r95", "r101", "r102", "r158", "r299", "r302", "r475", "r476", "r528", "r535", "r591", "r592", "r593", "r594", "r595", "r616", "r648", "r923", "r967" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactions", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionss" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r472", "r473", "r474", "r476", "r479", "r570", "r571", "r572", "r624", "r625", "r626", "r645", "r647" ] }, "limn_RepaymentOfMembershipInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "RepaymentOfMembershipInterest", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of repayment of membership interest.", "label": "Repayment Of Membership Interest", "terseLabel": "Repayment of membership interest" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Short-Term Debt", "negatedLabel": "Repayment of short-term debt, related party", "terseLabel": "Repayment of debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r95", "r103", "r104", "r236", "r277", "r478", "r499", "r526", "r670", "r671", "r672", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r899", "r900", "r901", "r902" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense related to the CD47 License", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r315", "r667", "r675", "r676", "r687", "r932" ] }, "limn_ResearchAndDevelopmentExpenseMandatoryCapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ResearchAndDevelopmentExpenseMandatoryCapitalization", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of research and development expense subject to mandatory capitalization.", "label": "Research and Development Expense, Mandatory Capitalization", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r314" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r30", "r47", "r533", "r555", "r556", "r568", "r599", "r731" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r63", "r64", "r65", "r105", "r106", "r107", "r109", "r116", "r118", "r120", "r192", "r193", "r209", "r261", "r312", "r341", "r342", "r349", "r350", "r351", "r353", "r407", "r408", "r418", "r420", "r421", "r423", "r430", "r466", "r467", "r552", "r554", "r574", "r969" ] }, "limn_RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts": { "xbrltype": "durationItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "RoyaltyFeesNumberOfYearsFromFirstCommercialSaleOfProducts", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of years from the first commercial sale of CAR-T product or CAR-T Diagnostic.", "label": "Royalty Fees, Number of Years From First Commercial Sale Of Products", "terseLabel": "Number of years from first commercial sale of products (in years)" } } }, "auth_ref": [] }, "limn_RoyaltyFeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "RoyaltyFeesPercentage", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty fees", "label": "Royalty Fees, Percentage", "terseLabel": "Percentage of royalty fees (%)" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "limn_ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ScenarioPriorToCompletionOfPhaseOneAndTwoClinicalTrialsForCarTProductMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining scenario being the scenario prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product.", "label": "Scenario, Prior To Completion of Phase One and Two Clinical Trials for CAR-T Product [Member]", "terseLabel": "Prior to the completion of the Phase I and Phase II clinical trials for the CAR-T product" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r68", "r70", "r121", "r304", "r766" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss" ], "lang": { "en-us": { "role": { "label": "Business Combination [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r203", "r354", "r355", "r356", "r357", "r363", "r364", "r365", "r366", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r401", "r402", "r403", "r406", "r712", "r715", "r896", "r897", "r898" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of income tax provision (benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r893" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r891" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r322", "r711", "r888" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTables", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsTabless" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value, assets and liabilities measured on recurring basis.", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r905", "r906" ] }, "limn_ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ScheduleOfOfferingProceedsAndRelatedIssuanceCostsTableTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of offering proceeds and related issuance costs.", "label": "Schedule of Offering Proceeds and Related Issuance Costs [Table Text Block]", "terseLabel": "Schedule of offering proceeds and related issuance costs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r95", "r101", "r102", "r475", "r476", "r478", "r622", "r623", "r626" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtTables", "http://www.liminatuspharma.com/role/DisclosureDebtTabless" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table Text Block]", "terseLabel": "Schedule of debt outstanding", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r19" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r155", "r157", "r685", "r686", "r689" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharePrice", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Closing stock price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "limn_SharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "SharesAuthorized", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of cumulative shares of all kinds permitted to be issued by an entity's charter and bylaws.", "label": "Shares Authorized", "terseLabel": "Shares authorized (in shares)", "verboseLabel": "Shares authorized" } } }, "auth_ref": [] }, "limn_SharesIssuableUponClosingOfMergerToUnderwriters": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "SharesIssuableUponClosingOfMergerToUnderwriters", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The fair value of stock issuable to underwriters upon closing of merger in a non-cash financing activities.", "label": "Shares Issuable Upon Closing Of Merger To Underwriters", "terseLabel": "Issuance of common stock to underwriter" } } }, "auth_ref": [] }, "limn_SharesIssuedForSurrenderAndCancellationOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "SharesIssuedForSurrenderAndCancellationOfWarrants", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for surrender and cancellation of warrants.", "label": "Shares Issued For Surrender And Cancellation Of Warrants", "terseLabel": "Number of shares issued for surrender and cancellation of warrants", "verboseLabel": "Issuance of common stock in connection with the surrender of warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Offering price (in dollar per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsAmantesLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsCarTcellkorLoanDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsEwonLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsHanaLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsProphaseLoansDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt", "terseLabel": "Short-term debt, related parties", "verboseLabel": "Amount borrowed", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18", "r50", "r731", "r934" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short term lease expense", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r469", "r730" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciess" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "State and Local" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r62", "r76", "r77", "r78", "r95", "r98", "r124", "r128", "r130", "r132", "r136", "r137", "r191", "r223", "r225", "r226", "r227", "r230", "r231", "r263", "r264", "r266", "r267", "r269", "r272", "r275", "r276", "r279", "r282", "r289", "r455", "r564", "r565", "r566", "r567", "r574", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r587", "r598", "r619", "r641", "r654", "r655", "r656", "r657", "r658", "r765", "r838", "r840", "r851" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityOfferingProceedsAndRelatedIssuanceCostsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r28", "r31", "r32", "r63", "r64", "r65", "r84", "r85", "r86", "r105", "r106", "r107", "r109", "r116", "r118", "r120", "r135", "r192", "r193", "r209", "r261", "r291", "r312", "r341", "r342", "r349", "r350", "r351", "r353", "r407", "r408", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r457", "r458", "r459", "r460", "r461", "r462", "r466", "r467", "r471", "r539", "r552", "r553", "r554", "r574", "r641" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r105", "r106", "r107", "r135", "r263", "r264", "r266", "r269", "r467", "r516", "r562", "r575", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r601", "r602", "r603", "r604", "r605", "r607", "r608", "r609", "r610", "r612", "r613", "r614", "r615", "r616", "r620", "r621", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r641", "r677", "r679", "r743", "r967" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Stockholders' Deficit" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r68", "r70", "r121", "r304", "r766", "r767" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r105", "r106", "r107", "r135", "r158", "r263", "r264", "r266", "r269", "r467", "r516", "r562", "r575", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r601", "r602", "r603", "r604", "r605", "r607", "r608", "r609", "r610", "r612", "r613", "r614", "r615", "r616", "r620", "r621", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r641", "r677", "r679", "r743", "r967" ] }, "limn_StatutoryStateIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StatutoryStateIncomeTaxRate", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of state statutory tax rate applicable to pretax income (loss).", "label": "Statutory State Income Tax Rate", "terseLabel": "California income tax rate" } } }, "auth_ref": [] }, "limn_StockIssuableForSettlementOfDeferredUnderwritingFees": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuableForSettlementOfDeferredUnderwritingFees", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable for settlement of deferred underwriting fees in connection with the underwriting services provided by the underwriters in the initial public offering.", "label": "Stock Issuable For Settlement Of Deferred Underwriting Fees", "terseLabel": "Stock issuable for settlement of deferred underwriting fees (in shares)", "verboseLabel": "Stock issuable for settlement of deferred underwriting fees" } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock Issued", "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r14", "r15", "r16" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r27", "r28", "r47" ] }, "limn_StockIssuedDuringPeriodSharesBusinessCombination": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedDuringPeriodSharesBusinessCombination", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to business combination.", "label": "Stock Issued During Period, Shares, Business Combination", "terseLabel": "Business combination with IRIS, net of transaction costs (in shares)" } } }, "auth_ref": [] }, "limn_StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedDuringPeriodSharesConversionOfDebtAndMemberUnits", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued in exchange for original debt being and member units being converted in connection with the consummation of business combination.", "label": "Stock Issued During Period, Shares, Conversion Of Debt And Member Units", "terseLabel": "Conversion of debt" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued (in shares)", "verboseLabel": "Issuance of common stock in connection with the Offering, net of offering costs of $559,962 (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r27", "r28", "r47", "r564", "r641", "r655" ] }, "limn_StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedDuringPeriodSharesSurrenderAndCancellationOfWarrants", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period for surrender and cancellation of warrants.", "label": "Stock Issued during The Period, Shares, Surrender And Cancellation Of Warrants", "terseLabel": "Issuance of common stock in connection with the Clear Street settlement (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock to Iris Acquisition Holdings, LLC", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r5", "r28", "r31", "r32", "r47" ] }, "limn_StockIssuedDuringPeriodValueBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedDuringPeriodValueBusinessCombination", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to business combination during the period.", "label": "Stock Issued During Period Value Business Combination", "terseLabel": "Business combination with IRIS, net of transaction costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock for the PIPE investment", "verboseLabel": "Issuance of common stock in connection with the Offering, net of offering costs of $559,962", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r27", "r28", "r47", "r574", "r641", "r655", "r749" ] }, "limn_StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedDuringPeriodValuesSurrenderAndCancellationOfWarrants", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period for surrender and cancellation of warrants.", "label": "Stock Issued during The Period, Values, Surrender And Cancellation Of Warrants", "terseLabel": "Issuance of common stock in connection with the Clear Street settlement" } } }, "auth_ref": [] }, "limn_StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedOrIssuableToUnderwritersUponConsummationOfBusinessCombination", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of shares issued or issuable to underwriters upon consummation of business combination in a non-cash transaction.", "label": "Stock Issued Or issuable To Underwriters Upon Consummation Of Business Combination", "terseLabel": "Fair value of shares to be issued to underwriter on date of the Business Combination" } } }, "auth_ref": [] }, "limn_StockIssuedPeriodOfCommonStockToUnderwriter": { "xbrltype": "sharesItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedPeriodOfCommonStockToUnderwriter", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued of common stock to underwriter", "label": "Stock issued Period of Common Stock to Underwriter", "terseLabel": "Issuance of common stock to underwriter (In shares)" } } }, "auth_ref": [] }, "limn_StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedPeriodValueForSurrenderAndCancellationOfWarrants", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued value for surrender and cancellation of warrants.", "label": "Stock issued Period Value For Surrender And Cancellation Of Warrants", "terseLabel": "Issuance of common stock in connection with the surrender of warrants" } } }, "auth_ref": [] }, "limn_StockIssuedPeriodValueOfCommonStockToUnderwriter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "StockIssuedPeriodValueOfCommonStockToUnderwriter", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued value of common stock to underwriter", "label": "Stock issued Period Value of Common Stock to Underwriter", "terseLabel": "Issuance of common stock to underwriter" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfChangesInStockholderSDeficit" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r28", "r31", "r32", "r43", "r600", "r617", "r642", "r643", "r731", "r750", "r836", "r840", "r841", "r870", "r918", "r969" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholder's Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureStockholderSEquity", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquitys" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholder's Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r46", "r274", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r291", "r417", "r429", "r644", "r646", "r659" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r463", "r481" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r463", "r481" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r463", "r481" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r463", "r481" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r463", "r481" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSubsequentEvents", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventss" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r480", "r482" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsLiquidityAndCapitalResourcesDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Description of Organization and Business Operations", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "limn_TenYearsPeriodFromFirstCommercialSaleOfProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "TenYearsPeriodFromFirstCommercialSaleOfProductMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining scenario being the net sale of period of 10 years from the first commercial sale of the CAR-T product or CAR-T Diagnostic until the product's patent expires in an individual country.", "label": "Ten Years Period From First Commercial Sale Of Product [Member]", "terseLabel": "10 years from first commercial sale of products" } } }, "auth_ref": [] }, "limn_ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ThresholdPeriodForRemainingDeferredUnderwritingFeeSettlementFromDateOfBusinessCombination", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for settling remaining deferred underwriting fee from the date of business combination.", "label": "Threshold Period For Remaining Deferred Underwriting Fee Settlement From Date of Business Combination", "terseLabel": "Threshold period for settling remaining deferred underwriting fee" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsDueToRelatedPartyDetailss" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r257", "r287", "r417", "r428", "r452", "r454", "r456", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r525", "r540", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r732", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r866", "r867", "r868", "r869", "r904", "r907", "r908", "r909", "r911", "r913", "r914", "r915" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCd47LicenseDetailss", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsTerminationOfLicenseAgreementDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r409" ] }, "limn_UnderwritingCostsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UnderwritingCostsNoncurrent", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of the carrying value as of balance sheet date of underwriting fees payable or classified as noncurrent.", "label": "Underwriting Costs Noncurrent", "terseLabel": "Underwriting discount" } } }, "auth_ref": [] }, "limn_UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UnderwritingDiscountAsPercentageOfGrossProceedsFromInitialPublicOffering", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of underwriting discount on gross proceeds of the IPO.", "label": "Underwriting Discount as Percentage of Gross Proceeds from Initial Public Offering", "terseLabel": "Underwriting discount (in percentage)" } } }, "auth_ref": [] }, "limn_UnderwritingDiscountPaidInSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UnderwritingDiscountPaidInSecurities", "crdr": "debit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.liminatuspharma.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "lang": { "en-us": { "role": { "documentation": "The amount paid in shares for offering costs.", "label": "Underwriting discount paid in securities", "terseLabel": "Underwriting discount paid in securities" } } }, "auth_ref": [] }, "limn_UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UnpaidAnnualMaintenanceFeesShortTermDebtInterestRate", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of interest rate of short-term debt being converted from the unpaid annual maintenance fees.", "label": "Unpaid Annual Maintenance Fees, Short - Term Debt, Interest Rate", "terseLabel": "Unpaid annual maintenance fees, short term debt interest rate (%)" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "verboseLabel": "Uncertain tax positions", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r317", "r329", "r710" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetails", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesIncomeTaxesDetailss" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r328", "r710" ] }, "limn_UnsecuredPromissoryNoteSettledAndConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UnsecuredPromissoryNoteSettledAndConverted", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetails", "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsBusinessCombinationDetailss" ], "lang": { "en-us": { "role": { "documentation": "Amount of unsecured promissory note was settled and related party debts were ultimately converted into shares of the Company in a noncash transaction.", "label": "Unsecured Promissory Note Settled and Converted", "terseLabel": "Unsecured promissory note settled and converted" } } }, "auth_ref": [] }, "limn_UpfrontPaymentOfLicenseAgreementFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "UpfrontPaymentOfLicenseAgreementFees", "crdr": "credit", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsCarTProductsLicenseDetails", "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront payment of license agreement fee.", "label": "Upfront Payment Of License Agreement Fees", "terseLabel": "Upfront payment of license agreement fees" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r59", "r60", "r138", "r139", "r140", "r141", "r520", "r522", "r681" ] }, "limn_VaccineLicenseAndDevelopmentAgreementWithTdtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "VaccineLicenseAndDevelopmentAgreementWithTdtMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to license and development agreement with TDT (the \"Vaccine License\"), whereby the Company received an exclusive license to develop and commercialize vaccine products (the \"Vaccine Products\") and a non-exclusive license to develop and commercialize companion diagnostics used to monitor treatment with a Vaccine Product (the \"Vaccine Diagnostics\").", "label": "Vaccine License And Development Agreement With Tdt [Member]", "terseLabel": "Vaccine license and development agreement with TDT" } } }, "auth_ref": [] }, "limn_VaccineProductsAndVaccineDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "VaccineProductsAndVaccineDiagnosticsMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureLicenseAgreementsVaccineProductsLicenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to product being vaccine products (the \"Vaccine Products\") and Vaccine Diagnostics.", "label": "Vaccine Products And Vaccine Diagnostics [Member]", "terseLabel": "Vaccine Products and Vaccine Diagnostics" } } }, "auth_ref": [] }, "limn_ValetudoAugust2023LoanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoAugust2023LoanOneMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo August 2023 Loans.", "label": "Valetudo August 2023 Loan One [Member]", "terseLabel": "Valetudo August 2023 Loan One" } } }, "auth_ref": [] }, "limn_ValetudoAugust2023LoanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoAugust2023LoanTwoMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo August 2023 Loan one.", "label": "Valetudo August 2023 Loan Two [Member]", "terseLabel": "Valetudo August 2023 Loan Two" } } }, "auth_ref": [] }, "limn_ValetudoAugust2023LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoAugust2023LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo August 2023 Loans.", "label": "Valetudo August 2023 Loans [Member]", "terseLabel": "Valetudo August 2023 Loans" } } }, "auth_ref": [] }, "limn_ValetudoDecember2022LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoDecember2022LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo December 2022 Loan.", "label": "Valetudo December 2022 Loan [Member]", "terseLabel": "Valetudo December 2022 Loan" } } }, "auth_ref": [] }, "limn_ValetudoDecember2022LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoDecember2022LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo December 2022 Loans.", "label": "Valetudo December 2022 Loans [Member]", "terseLabel": "Valetudo Loan" } } }, "auth_ref": [] }, "limn_ValetudoJanuary2024LoanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJanuary2024LoanOneMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo January 2024 Loan one.", "label": "Valetudo January 2024 Loan One [Member]", "terseLabel": "Valetudo January 2024 Loan One" } } }, "auth_ref": [] }, "limn_ValetudoJanuary2024LoanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJanuary2024LoanTwoMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo January 2024 Loan two.", "label": "Valetudo January 2024 Loan Two [Member]", "terseLabel": "Valetudo January 2024 Loan Two" } } }, "auth_ref": [] }, "limn_ValetudoJanuary2024LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJanuary2024LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo January 2024 Loans.", "label": "Valetudo January 2024 Loans [Member]", "terseLabel": "Valetudo January 2024 Loans" } } }, "auth_ref": [] }, "limn_ValetudoJuly2023LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJuly2023LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo July 2023 Loan.", "label": "Valetudo July 2023 Loan [Member]", "terseLabel": "Valetudo July 2023 Loan" } } }, "auth_ref": [] }, "limn_ValetudoJune2023LoanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJune2023LoanOneMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo June 2023 Loans.", "label": "Valetudo June 2023 Loan One [Member]", "terseLabel": "Valetudo June 2023 Loan One" } } }, "auth_ref": [] }, "limn_ValetudoJune2023LoanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJune2023LoanTwoMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo June 2023 Loan one.", "label": "Valetudo June 2023 Loan Two [Member]", "terseLabel": "Valetudo June 2023 Loan Two" } } }, "auth_ref": [] }, "limn_ValetudoJune2023LoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoJune2023LoansMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetails", "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo June 2023 Loans.", "label": "Valetudo June 2023 Loans [Member]", "terseLabel": "Valetudo June 2023 Loans" } } }, "auth_ref": [] }, "limn_ValetudoLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoLoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo Loan.", "label": "Valetudo Loan [Member]", "terseLabel": "Valetudo Loan" } } }, "auth_ref": [] }, "limn_ValetudoNovember2023LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoNovember2023LoanMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDebtDetailss", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining toValetudo January 2024 Loans.", "label": "Valetudo November 2023 Loan [Member]", "terseLabel": "Valetudo November 2023 Loan" } } }, "auth_ref": [] }, "limn_ValetudoTherapeuticsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ValetudoTherapeuticsLlcMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsValetudoLoansDetailss" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Valetudo Therapeutics LLC.", "label": "Valetudo Therapeutics LLC [Member]", "terseLabel": "Valetudo Therapeutics LLC" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetailss": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesDetails", "http://www.liminatuspharma.com/role/DisclosureIncomeTaxesIncomeTaxProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r332" ] }, "limn_ViralGeneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "ViralGeneMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsViralGeneDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Viral Gene.", "label": "Viral Gene [Member]", "terseLabel": "Viral Gene" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Details", "http://www.liminatuspharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3Detailss" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r740", "r741", "r744", "r745", "r746", "r747" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.liminatuspharma.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r907", "r908", "r909" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityAssumptionsUsedForEstimatingFairValueOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r907", "r908", "r909" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsFebruary2026PublicOfferingDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetails", "http://www.liminatuspharma.com/role/DisclosureRelatedPartyTransactionsFeeluxBondsDetailss", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetails", "http://www.liminatuspharma.com/role/DisclosureStockholderSEquityDetailss", "http://www.liminatuspharma.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Contractual term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r907", "r908", "r909" ] }, "limn_WarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.liminatuspharma.com/20260331", "localname": "WarrantsPolicyPolicyTextBlock", "presentation": [ "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPolicies", "http://www.liminatuspharma.com/role/DisclosureSignificantAccountingPoliciesPoliciess" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants, Policy [Policy Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r123", "r132" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.liminatuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.liminatuspharma.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r122", "r132" ] } } }, "limn-20260331xexfees.htm": { "dts": { "inline": { "local": [ "limn-20260331xexfees.htm" ] }, "schema": { "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 8, "http://xbrl.sec.gov/ffd/2026": 6, "http://xbrl.sec.gov/dei/2026": 2 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 107, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/ffd/2026": 22, "http://xbrl.sec.gov/dei/2026": 3 }, "report": { "R88": { "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable", "longName": "995210 - Document - Submission", "shortName": "Submission", "isDefault": "true", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "88", "firstAnchor": null, "uniqueAnchor": null }, "R89": { "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "longName": "995211 - Document - Offerings", "shortName": "Offerings", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "89", "firstAnchor": { "contextRef": "offrl_1", "name": "ffd:PrevslyPdFlg", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xexfees.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "offrl_1", "name": "ffd:PrevslyPdFlg", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xexfees.htm", "first": true, "unique": true } }, "R90": { "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable", "longName": "995215 - Document - Fees Summary", "shortName": "Fees Summary", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "90", "firstAnchor": { "contextRef": "rc", "name": "ffd:TtlOfferingAmt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xexfees.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "rc", "name": "ffd:TtlOfferingAmt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "limn-20260331xexfees.htm", "first": true, "unique": true } } }, "tag": { "ffd_AggtRedRpPricFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtRedRpPricFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year", "terseLabel": "Aggregate Redeemed or Repurchased, FY" } } }, "auth_ref": [ "r752" ] }, "ffd_AggtRedRpPricPrrFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtRedRpPricPrrFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year", "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY" } } }, "auth_ref": [ "r752" ] }, "ffd_AggtSalesPricFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtSalesPricFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Sales Price, Fiscal Year", "terseLabel": "Aggregate Sales Price" } } }, "auth_ref": [ "r752" ] }, "ffd_AmtRedCdts": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtRedCdts", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Amount of Redemption Credits", "terseLabel": "Redemption Credits" } } }, "auth_ref": [ "r752" ] }, "ffd_AmtSctiesRcvd": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtSctiesRcvd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Amount of Securities Received", "terseLabel": "Amount of Securities Received", "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)" } } }, "auth_ref": [ "r757" ] }, "ffd_AmtSctiesRegd": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtSctiesRegd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Amount of Securities Registered", "terseLabel": "Amount Registered", "documentation": "The amount of securities being registered." } } }, "auth_ref": [ "r752" ] }, "ffd_CeasedOprsDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CeasedOprsDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Ceased Operations Date", "terseLabel": "Ceased Operations Date" } } }, "auth_ref": [] }, "ffd_CfwdFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Form Type", "terseLabel": "Carry Forward Form Type", "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)." } } }, "auth_ref": [ "r753" ] }, "ffd_CfwdPrevslyPdFee": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrevslyPdFee", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Previously Paid Fee", "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward", "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)." } } }, "auth_ref": [ "r753" ] }, "ffd_CfwdPrrFctvDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrrFctvDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Prior Effective Date", "terseLabel": "Carry Forward Initial Effective Date", "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)." } } }, "auth_ref": [ "r753" ] }, "ffd_CfwdPrrFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrrFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward File Number", "terseLabel": "Carry Forward File Number", "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used." } } }, "auth_ref": [ "r753" ] }, "ffd_CmbndPrspctsItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsItemAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus Item [Axis]", "terseLabel": "Combined Prospectus", "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission." } } }, "auth_ref": [ "r752" ] }, "ffd_CmbndPrspctsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsLineItems", "lang": { "en-us": { "role": { "label": "Combined Prospectus [Line Items]", "terseLabel": "Combined Prospectus:" } } }, "auth_ref": [ "r752" ] }, "ffd_CmbndPrspctsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus [Table]", "terseLabel": "Combined Prospectus Table" } } }, "auth_ref": [ "r752" ] }, "ffd_CombinedProspectusTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CombinedProspectusTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus Table [N/A]", "terseLabel": "Combined Prospectus Table N/A" } } }, "auth_ref": [] }, "ffd_CshPdByRegistrantInTx": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CshPdByRegistrantInTx", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Cash Paid by Registrant in Transaction", "terseLabel": "Cash Consideration Paid", "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)." } } }, "auth_ref": [ "r763" ] }, "ffd_CshRcvdByRegistrantInTx": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CshRcvdByRegistrantInTx", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Cash Received by Registrant in Transaction", "terseLabel": "Cash Consideration Received", "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)." } } }, "auth_ref": [ "r763" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r751" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r751" ] }, "ffd_FeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Amount", "terseLabel": "Amount of Registration Fee", "documentation": "Total amount of registration fee (amount due after offsets)." } } }, "auth_ref": [ "r752" ] }, "ffd_FeeExhibitTp": { "xbrltype": "feeExhibitTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeExhibitTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Fee Exhibit Type", "terseLabel": "Fee Exhibit Type" } } }, "auth_ref": [] }, "ffd_FeeIntrstAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeIntrstAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Fee Interest Amount", "terseLabel": "Interest Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_FeeNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Note", "terseLabel": "Fee Note" } } }, "auth_ref": [ "r752" ] }, "ffd_FeeNoteMaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeNoteMaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Fee Note Maximum Aggregate Offering Price", "terseLabel": "Fee Note MAOP" } } }, "auth_ref": [ "r752" ] }, "ffd_FeeRate": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeRate", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Rate", "terseLabel": "Fee Rate", "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission." } } }, "auth_ref": [ "r752" ] }, "ffd_FeesOthrRuleFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeesOthrRuleFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Fees, Other Rule [Flag]", "terseLabel": "Other Rule", "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due." } } }, "auth_ref": [ "r752" ] }, "ffd_FeesSummaryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeesSummaryLineItems", "lang": { "en-us": { "role": { "label": "Fees Summary [Line Items]", "terseLabel": "Fees Summary:" } } }, "auth_ref": [ "r752" ] }, "ffd_FnlPrspctsFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FnlPrspctsFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Final Prospectus [Flag]", "terseLabel": "Final Prospectus" } } }, "auth_ref": [ "r752" ] }, "ffd_FormTp": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Form Type", "terseLabel": "Form Type" } } }, "auth_ref": [] }, "ffd_GnlInstrIIhiFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "GnlInstrIIhiFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "General Instruction II.H,I [Flag]", "terseLabel": "General Instruction II.H,I" } } }, "auth_ref": [] }, "ffd_IssrBizAdrCity": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrCity", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, City", "terseLabel": "City" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStatOrCtryCd": { "xbrltype": "stateOrCountryCodeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStatOrCtryCd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, State or Country Code", "terseLabel": "State or Country Code" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStrt1": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStrt1", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Street 1", "terseLabel": "Street 1" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStrt2": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStrt2", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Street 2", "terseLabel": "Street 2" } } }, "auth_ref": [] }, "ffd_IssrBizAdrZipCd": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrZipCd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Zip Code", "terseLabel": "Zip Code" } } }, "auth_ref": [] }, "ffd_IssrNm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrNm", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Name", "terseLabel": "Issuer Name" } } }, "auth_ref": [] }, "ffd_MaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "MaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Maximum Aggregate Offering Price", "terseLabel": "Maximum Aggregate Offering Price", "documentation": "The maximum aggregate offering price for the offering that is being registered." } } }, "auth_ref": [ "r752" ] }, "ffd_MaxOfferingPricPerScty": { "xbrltype": "nonNegativeDecimal4lItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "MaxOfferingPricPerScty", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Maximum Offering Price per Security", "terseLabel": "Proposed Maximum Offering Price per Unit", "documentation": "The maximum offering price per share/unit being registered." } } }, "auth_ref": [ "r752" ] }, "ffd_NetFeeAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NetFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Net Fee Amount", "terseLabel": "Net Fee" } } }, "auth_ref": [ "r752" ] }, "ffd_NetSalesAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NetSalesAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Net Sales Amount", "terseLabel": "Net Sales" } } }, "auth_ref": [ "r752" ] }, "ffd_NrrtvDsclsr": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvDsclsr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure", "terseLabel": "Narrative Disclosure" } } }, "auth_ref": [ "r752" ] }, "ffd_NrrtvMaxAggtAmt": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvMaxAggtAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure, Maximum Aggregate Offering Amount", "terseLabel": "Narrative - Max Aggregate Offering Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_NrrtvMaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvMaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure, Maximum Aggregate Offering Price", "terseLabel": "Narrative - Max Aggregate Offering Price" } } }, "auth_ref": [ "r752" ] }, "ffd_OfferingAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering [Axis]", "terseLabel": "Offering", "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission." } } }, "auth_ref": [] }, "ffd_OfferingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingLineItems", "lang": { "en-us": { "role": { "label": "Offering [Line Items]", "terseLabel": "Offering:" } } }, "auth_ref": [] }, "ffd_OfferingNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering Note", "terseLabel": "Offering Note" } } }, "auth_ref": [ "r752" ] }, "ffd_OfferingSctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingSctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Offering Security Title", "terseLabel": "Security Class Title", "documentation": "The title of the class of securities being registered (for each class being registered)." } } }, "auth_ref": [ "r752" ] }, "ffd_OfferingSctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingSctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering Security Type", "terseLabel": "Security Type", "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\"" } } }, "auth_ref": [ "r752" ] }, "ffd_OfferingTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering [Table]", "terseLabel": "Offering:" } } }, "auth_ref": [] }, "ffd_OfferingTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Offering Table [N/A]", "terseLabel": "Offering Table N/A" } } }, "auth_ref": [] }, "ffd_OffsetAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset [Axis]", "terseLabel": "Offset", "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission." } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetClmInitlFilgDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmInitlFilgDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claim Initial Filing Date", "terseLabel": "Initial Filing Date", "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetClmdAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claimed Amount", "terseLabel": "Fee Offset Claimed", "documentation": "The amount of offsetting fees being claimed." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetClmdInd": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmdInd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claimed Indicator", "terseLabel": "Offset Claimed" } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetExpltnForClmdAmt": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetExpltnForClmdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Explanation for Claimed Amount", "terseLabel": "Explanation for Claimed Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetLineItems", "lang": { "en-us": { "role": { "terseLabel": "Offset:", "label": "Offset [Line Items]" } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Note", "terseLabel": "Offset Note" } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetPrrFeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Fee Amount", "terseLabel": "Fee Paid with Fee Offset Source", "documentation": "The fee previously paid from which an offset is being derived." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior File Number", "terseLabel": "File Number", "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrFilerNm": { "xbrltype": "filerNameItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFilerNm", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Filer Name", "terseLabel": "Registrant or Filer Name", "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Form Type", "terseLabel": "Form or Filing Type", "documentation": "The Form Type of the offset filing." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrNbOfUnsoldScties": { "xbrltype": "nonNegativeDecimal8ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrNbOfUnsoldScties", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Unsold Number of Securities", "terseLabel": "Unsold Securities Associated with Fee Offset Claimed", "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrSctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrSctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Security Title", "terseLabel": "Security Title Associated with Fee Offset Claimed", "documentation": "The title of the class of securities from which offset fees were derived." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrSctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrSctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Security Type", "terseLabel": "Security Type Associated with Fee Offset Claimed", "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\"" } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetPrrUnsoldOfferingAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrUnsoldOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Unsold Offering Amount", "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed", "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetSrcFilgDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetSrcFilgDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Source Filing Date", "terseLabel": "Filing Date", "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset." } } }, "auth_ref": [ "r756", "r759" ] }, "ffd_OffsetTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Offset Payment:", "label": "Offset [Table]" } } }, "auth_ref": [ "r752" ] }, "ffd_OffsetTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Offset Table [N/A]", "terseLabel": "Offset Table N/A" } } }, "auth_ref": [] }, "ffd_PrevslyPdFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "PrevslyPdFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Previously Paid [Flag]", "terseLabel": "Fee Previously Paid" } } }, "auth_ref": [] }, "ffd_RegnFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "RegnFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Registration File Number", "terseLabel": "Registration File Number" } } }, "auth_ref": [] }, "ffd_RptgFsclYrEndDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "RptgFsclYrEndDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Reporting Fiscal Year End Date", "terseLabel": "Reporting FY End Date" } } }, "auth_ref": [] }, "ffd_Rule011Flg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule011Flg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 0-11 [Flag]", "terseLabel": "Rule 0-11" } } }, "auth_ref": [] }, "ffd_Rule011a2OffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule011a2OffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 0-11(a)(2) Offset", "label": "Rule 0-11(a)(2) Offset [Flag]" } } }, "auth_ref": [] }, "ffd_Rule415a6Flg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule415a6Flg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 415(a)(6) [Flag]", "terseLabel": "Rule 415(a)(6)", "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward." } } }, "auth_ref": [ "r753" ] }, "ffd_Rule429AggtOfferingAmt": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429AggtOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Aggregate Offering Amount", "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered", "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429CmbndPrspctsFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429CmbndPrspctsFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Combined Prospectus [Flag]", "terseLabel": "Rule 429", "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429EarlierFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429EarlierFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Earlier File Number", "terseLabel": "File Number", "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429EarlierFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429EarlierFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Earlier Form Type", "terseLabel": "Form Type", "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429InitlFctvDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429InitlFctvDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Initial Effective Date", "terseLabel": "Initial Effective Date", "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429NbOfUnsoldScties": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429NbOfUnsoldScties", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Number Of Unsold Securities", "terseLabel": "Amount of Securities Previously Registered", "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429." } } }, "auth_ref": [ "r754" ] }, "ffd_Rule429PrspctsNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429PrspctsNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Prospectus Note", "terseLabel": "Combined Prospectus Note" } } }, "auth_ref": [ "r752" ] }, "ffd_Rule429SctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429SctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Security Title", "terseLabel": "Security Class Title" } } }, "auth_ref": [ "r752" ] }, "ffd_Rule429SctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429SctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Security Type", "terseLabel": "Security Type" } } }, "auth_ref": [ "r752" ] }, "ffd_Rule457aFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457aFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(a) [Flag]", "terseLabel": "Rule 457(a)", "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due." } } }, "auth_ref": [ "r755" ] }, "ffd_Rule457bOffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457bOffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(b) Offset [Flag]", "terseLabel": "Rule 457(b) Offset", "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)." } } }, "auth_ref": [ "r756" ] }, "ffd_Rule457fFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457fFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(f) [Flag]", "terseLabel": "Rule 457(f)", "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due." } } }, "auth_ref": [ "r757" ] }, "ffd_Rule457oFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457oFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(o) [Flag]", "terseLabel": "Rule 457(o)", "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due." } } }, "auth_ref": [ "r758" ] }, "ffd_Rule457pOffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457pOffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(p) Offset [Flag]", "terseLabel": "Rule 457(p) Offset", "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)." } } }, "auth_ref": [ "r759" ] }, "ffd_Rule457rFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457rFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(r) [Flag]", "terseLabel": "Rule 457(r)" } } }, "auth_ref": [ "r760" ] }, "ffd_Rule457sFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457sFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(s) Flag", "terseLabel": "Rule 457(s)" } } }, "auth_ref": [ "r761" ] }, "ffd_Rule457uFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457uFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(u) [Flag]", "terseLabel": "Rule 457(u)", "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due." } } }, "auth_ref": [ "r762" ] }, "ffd_Scties424iAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Securities, 424I [Axis]", "terseLabel": "Securities, 424I" } } }, "auth_ref": [ "r752" ] }, "ffd_Scties424iLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iLineItems", "lang": { "en-us": { "role": { "label": "Securities, 424I [Line Items]", "terseLabel": "Securities, 424I:" } } }, "auth_ref": [ "r752" ] }, "ffd_Scties424iTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Securities, 424I [Table]", "terseLabel": "Securities, 424I Table" } } }, "auth_ref": [ "r752" ] }, "ffd_Securities424iTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Securities424iNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Securities 424I [N/A]", "terseLabel": "Securities 424I N/A" } } }, "auth_ref": [] }, "ffd_SubmissionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "SubmissionLineItems", "lang": { "en-us": { "role": { "label": "Submission [Line Items]", "terseLabel": "Items" } } }, "auth_ref": [] }, "ffd_SubmissnTp": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "SubmissnTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Submission Type", "terseLabel": "Submission Type" } } }, "auth_ref": [] }, "ffd_TermntnCmpltnWdrwl": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TermntnCmpltnWdrwl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Termination / Completion / Withdrawal Statement", "terseLabel": "Termination / Withdrawal Statement" } } }, "auth_ref": [] }, "ffd_TtlFeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Fee Amount", "terseLabel": "Total Fee Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_TtlFeeAndIntrstAmt": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlFeeAndIntrstAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Fee and Interest Amount", "terseLabel": "Total Fee and Interest Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_TtlOfferingAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Offering Amount", "terseLabel": "Total Offering" } } }, "auth_ref": [ "r752" ] }, "ffd_TtlOffsetAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlOffsetAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Offset Amount", "terseLabel": "Total Offset Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_TtlPrevslyPdAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlPrevslyPdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Previously Paid Amount", "terseLabel": "Previously Paid Amount" } } }, "auth_ref": [ "r752" ] }, "ffd_TtlTxValtn": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlTxValtn", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Transaction Valuation", "terseLabel": "Total Transaction Valuation" } } }, "auth_ref": [ "r752" ] }, "ffd_TxValtn": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TxValtn", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Transaction Valuation", "terseLabel": "Transaction Valuation" } } }, "auth_ref": [] }, "ffd_ValSctiesRcvd": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "ValSctiesRcvd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Value of Securities Received", "terseLabel": "Value of Securities Received", "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)" } } }, "auth_ref": [ "r757" ] }, "ffd_ValSctiesRcvdPerShr": { "xbrltype": "nonNegativeDecimal4lItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "ValSctiesRcvdPerShr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Value of Securities Received, Per Share", "terseLabel": "Value of Securities Received, Per Share", "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation." } } }, "auth_ref": [ "r757" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-4" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "415", "Subsection": "a" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "429" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "b" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "f" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "o" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "p" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "r" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "s" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "u" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Subsection": "f", "Section": "457" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r765": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r767": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }